Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Cheil

Cheil Worldwide Inc.

Premium
Information Technology

Cheil Worldwide is Korea's largest advertising and marketing-services company and the global lead agency for Samsung Electronics and other Samsung affiliates. It earns gross profit from creative, digital, retail/experiential, media and data services delivered through a Seoul headquarters and roughly 50 subsidiaries and branches across about 45–47 countries. Overseas subsidiaries generate close to four-fifths of gross profit. Digital services, chiefly Samsung.com and other D2C/e-commerce operations, performance media, CRM and content production, accounted for 55% of FY2025 gross profit. Affiliate (Samsung) work made up 71% of FY2025 gross profit and non-affiliate clients 29%. That structure gives Cheil a stable, cash-generative base: net cash of about KRW 840bn excluding leases at end-2025, and a 60% consolidated payout. It also ties growth closely to Samsung's marketing budgets. Management is repositioning the company as an AI- and data-enabled "marketing tech solution partner" while increasing shareholder returns through dividends and, from 2026, the cancellation of treasury shares. --- ### Company's own description (FY2025 Business Report, paraphrased) Cheil describes advertising as its main business. It offers marketing solutions aimed at maximising advertisers' marketing results, falling broadly into (i) advertising planning and production and (ii) media selection and buying (TV, radio, out-of-home and others). As the marketing environment has digitised, it has added AdTech-based services such as analysis of consumers' online purchase behaviour and personalised marketing strategy. The annual report groups capabilities into five fields: Strategy (supported by the Cheil DnA — Data and Analytics — Center), Creative, Digital, Experiential (events, exhibitions, sports, retail marketing) and Media (planning and buying across the four major media, cable, internet, DMB, OOH, sports and special advertising). The overarching proposition is "practical and applied solutions" that prompt consumer action at online and offline touchpoints and directly affect sales. ### Business model and revenue model - **Service-based model, no products or licensing of significance.** Revenue comes from (a) media agency commissions and fees, (b) fees and pass-through billing for production, digital operations, retail/BTL execution and events, and (c) consulting and data/technology solutions. The parent company's separate accounts split operating revenue into media agency (KRW 104.2bn in FY2025: broadcast 11.3bn, print 32.8bn, new media 60.1bn) and "advertising production, etc." (KRW 1,311.4bn) (FY2025 Annual Report). **Gross profit is the economic top line:** Much of statutory revenue is third-party production and media cost passed through to clients. Cost of sales was KRW 2,687.0bn on revenue of KRW 4,546.9bn in FY2025, giving a gross-profit-to-revenue ratio of 40.9%. **Fee structures:** retainers, project fees, media commissions and performance-linked arrangements are standard in the industry. Cheil does not publicly disclose the mix by contract type. **Subscription/SaaS:** not material. AI and data tools such as Connect AI, CMDB and Cheil Optimizer+ are deployed internally and as client solutions, but their revenue is not separately disclosed. ### Value-chain position Cheil sits between advertisers and media/production suppliers. Its role spans strategy and creative ideation through content production, media planning and buying, D2C platform operation (notably Samsung.com in many countries), retail execution (in-store promotion, brand stores, shopper marketing) and measurement. Its captive relationship with Samsung puts it unusually deep in the client's commercial operations: dotcom, CRM and retail are operational services, not just communications. ### Customer types and end-markets **Affiliate clients (71% of FY2025 GP):** Samsung Electronics (consumer electronics, mobile, appliances, B2B), Samsung Life, Samsung Fire & Marine, Samsung Card, Samsung Securities, Samsung C&T (construction, fashion), Samsung Biologics/Bioepis, Hotel Shilla, S-1, Samsung Heavy Industries, Samsung E&A, Samsung Display, Samsung Electro-Mechanics and others (client list, FY2025 Annual Report, as of March 2026). Daishin Securities (30 Apr 2026) estimates that Samsung Electronics' marketing spend drives about 70% of Cheil's domestic and overseas results. **Non-affiliate clients (29% of FY2025 GP):** a broad mix including KT, Naver, Nexon, Shinhan Financial Group, Dunamu (Upbit), Netflix, Google Korea, Universal Pictures, Burger King, Nongshim, Dongsuh Foods, Amorepacific, lululemon, Skechers, BYD, Hankook Tire, IKEA (North America), Philip Morris (Europe, North America, SEA), Henkel, Bosch, Beiersdorf, Alcon, Biogen, AMEX, Little Caesars, Popeyes, Moutai, Yili, China Construction Bank, Changan, BMW China, Audi-Volkswagen (China, Middle East), Etisalat, MG Motor (South West Asia) and Decathlon (Latin America) (FY2025 Annual Report client list). **End-markets by industry:** IT/electronics, financial services, consumer services, food and beverage, pharmaceuticals and healthcare, cosmetics, fashion, transport and automotive, chemicals, construction and others. ### Independent characterisation Cheil is best understood as a captive-anchored, digitally weighted global marketing operator rather than a classic creative agency network. Three features stand out: 1. **Earnings quality is high but concentrated.** Gross profit grew in each year from 2021 to 2025, and operating profit grew in four of those five years. Even so, roughly seven-tenths of GP depends on one client group's budget cycle. The 2026 slowdown shows this directly: analysts link it to Samsung's mobile (MX) division tightening marketing budgets as memory-price increases squeezed device margins. 2. **Digital is mostly operations-heavy D2C work.** The 55–56% digital share includes Samsung.com operation, e-commerce, CRM and performance media. These are stickier and less exposed to fee compression than pure creative work, but they are labour-intensive. 3. **Low capital intensity and net cash.** Capex was about KRW 40bn a year in 2024–2025 (PP&E plus intangibles). Net cash excluding leases was about KRW 840bn at end-2025. That supports a 60% payout and the 2026 buyback-and-cancellation programme.

RevenueN/A
Employees1,511
Market CapN/A
Founded1973
United States, North America

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Cellumed

Cellumed Co., Ltd.

Premium
Information Technology

Cellumed is a Seoul-based medical-device and tissue-biologics company. It started as an industrial firm (Newtechman), listed on KOSDAQ in 2002, and took on its musculoskeletal and biologics identity through the 2010 merger with Korea Bone Bank. Its medical franchise rests on licensed human-tissue banking. Key products include demineralized bone matrix (Rafugen DBM, Rafugen Dental), acellular dermal matrix (the CELLUDERM family), recombinant human BMP-2 and FGF growth factors, and a titanium-alloy total-knee system. In economic terms, however, the group is now mostly a building-services contractor. Its subsidiary Hwangyeong ENG (환경이엔지), which does mechanical and fire-protection installation, produced about 93% of consolidated revenue in Q2 2026. The equity story since 2025 has been driven by solvency, not operations. A US royalty judgment, capital impairment, administrative-issue designation, repeated non-clean auditor review opinions, a change of control to an investment partnership, and a pending KRX delisting review now matter more to the valuation than product performance. --- ### What the company does Cellumed operates two economically distinct businesses within one listed shell. **(a) Medical / biologics (parent company).** Cellumed holds a human tissue bank licence (granted 2005) and a licence to manufacture human-tissue-based medical devices (granted 2007). Under these it processes donated human tissue into: **Bone graft materials:** demineralized bone matrix (DBM) in gel and powder forms for orthopaedic and spinal fusion (Rafugen DBM, Rafugen DBM Gel Pro), and dental bone graft (Rafugen Dental, also called Dental Powder). **Skin / soft-tissue grafts:** acellular allogeneic dermis (CELLUDERM HD IMPLANT, CELLUDERM POWER, CELLUDERM ULTRA). Injectable forms, CELLUDERM FILL and CELLUDERM GEN, have completed development. These are used in breast reconstruction, plastic surgery, urology and "men's/women's medicine" indications. The company also makes: **Recombinant protein biologics:** rhBMP-2 (bone morphogenetic protein 2, used for bone regeneration). Cellumed describes itself as the second company in the world and the first in Asia to mass-produce rhBMP-2. It also makes FGF (fibroblast growth factor, including FGF7), which is used as a cosmetic ingredient. **Orthopaedic implants and instruments:** a total-knee replacement whose femoral and tibial components are both titanium alloy (claimed to be the first such domestically produced product in Korea), spinal fixation systems, navigation systems, and 3D-printed patient-specific instruments (PSI) for knee arthroplasty. **Cosmeceuticals:** the Dermycos (더미코스) line based on FGF7. It was listed at Shilla Duty Free in 2021. **Exploratory programmes:** enzymes used to produce mRNA vaccines and therapeutics, through subsidiary Cellumed Biologics (founded August 2022 in Songdo, Incheon) and contract development with a German partner. In 2023 the company also announced plans for swappable-battery packs and electric two-wheelers. **(b) Construction machinery & equipment installation (subsidiaries).** In 2019 Cellumed acquired InsGreen (인스그린, environmental-facilities construction) and Hwangyeong ENG (환경이엔지, general mechanical/building-services installation). Hwangyeong ENG installs HVAC, plumbing and fire-protection systems as a subcontractor to Korea's top-tier general contractors. Its projects include apartment complexes (including an LH Korea Land & Housing site in Wonju), commercial buildings (a department store renovation in Daegu) and infrastructure (Korean Air Incheon T2-related works). It reported record revenue above KRW 100 bn in FY2024 and an order backlog of about KRW 140 bn in December 2025 (Asia Economy, 4 December 2025). ### Business and revenue model | Dimension | Medical / biologics | Construction equipment installation | |---|---|---| | Revenue type | Product sales (tissue grafts, implants, devices, proteins, cosmetics) | Contract revenue, recognised by percentage of completion on subcontracted installation work | | Customers | University and specialist hospitals, orthopaedic and spine surgeons, dental clinics and networks, plastic surgery and breast surgery clinics; overseas distributors for DBM | Top-tier Korean general contractors (named as a "preferred partner" by several); public housing (LH); commercial developers | | Pricing | Largely regulated by Korea's national health-insurance reimbursement for reimbursed items; specific prices not publicly disclosed | Competitive tender / negotiated subcontract | | Value-chain position | Tissue processor and manufacturer (sources donor tissue, partly from global suppliers per the company); also an R&D originator for recombinant proteins | Specialist subcontractor below general contractors | | Approximate revenue share | ~7% of consolidated revenue (Q2 2026) | ~93% of consolidated revenue (Q2 2026) | Product vs. service vs. subscription vs. licensing mix: in substance, almost all revenue is either product sales (medical) or contract/service revenue (construction). No subscription or licensing revenue is disclosed. Notably, the company has been a payer of royalties: the US Buechel-Pappas litigation relates to royalties owed for artificial-joint technology. ### Company's own description vs. independent characterisation - **Company's own framing (paraphrased from the FY2025 Business Report and press releases):** Cellumed calls itself a bio-medical-device manufacturer. It traces its lineage to Newtechman (1985), its KOSDAQ listing (2002), and the 2010 Korea Bone Bank merger, which took it into medical devices and biosimilars. Its press releases consistently use the label "bio medical device specialist manufacturer" (바이오 의료기기 전문 제조기업). The DART industry classification is basic pharmaceutical substances and biological products manufacturing. **Independent characterisation:** By revenue, Cellumed is a building-services contractor with an attached, sub-scale tissue-biologics franchise. The medical business shrank from KRW 14.6 bn (FY2022) to KRW 14.1 bn (FY2023) and KRW 8.6 bn in 9M2024 (Dealsite, March 2025). Meanwhile construction grew to more than 87% of revenue. The medical assets (licences, FDA-listed DBM, rhBMP-2 process know-how, ADM line) carry strategic option value. This was shown by L&C Bio Group's interest in December 2025, which was later abandoned. But the medical business is not large enough to carry group overheads, litigation costs or financing needs.

Revenue$0.1B
Employees55
Market CapN/A
Founded1985
United States, North America
Cellivery

Cellivery Therapeutics, Inc.

Premium
Information Technology

Cellivery Therapeutics was founded in 2014 as a platform biotech built around a protein-delivery technology originally called MITT (Macromolecule Intracellular Transduction Technology) and later rebranded TSDT (Therapeutic Molecule Systemic Delivery Technology), which the company claimed could carry large recombinant proteins across cell membranes and the blood-brain barrier. In November 2018 it became the first company admitted to KOSDAQ under the underwriter-recommended "growth special listing" track, and during the COVID-19 period its market value briefly exceeded KRW 3 trillion on expectations for its Parkinson's candidate iCP-Parkin and anti-inflammatory iCP-NI. No candidate advanced beyond an early Phase 1 trial and no external licensing deal was ever disclosed. After diverting capital-markets proceeds into the acquisition of a wet-tissue maker, the company received consecutive audit disclaimers, was delisted in March 2025, and is now a near-dormant unlisted entity controlled by former minority shareholders. --- **What the company did (as designed).** Cellivery positioned itself as a drug-delivery platform company. Its core claim was that by fusing therapeutic proteins with engineered peptide sequences, it could produce "cell-permeable" recombinant proteins (branded iCP- or CP-) able to enter cells and tissues, including deep brain tissue, which conventional biologics cannot easily reach. Upon IPO in 2018, the prospectus described four protein-based drug candidates — iCP-Parkin (Parkinson's disease), iCP-SOCS3 (pancreatic cancer), CP-BMP2 (bone formation), and CP-ΔSOCS3 (severe obesity) — plus three lines of cell-permeable research reagents (iCP-Cre, six iCP-RF reprogramming factors, and CP-Cas9) (Dailypharm, 9 Nov 2018, citing the investment prospectus). **Business model and revenue model.** The intended model was a classic platform-licensing model: (i) out-license individual candidates after preclinical or early clinical proof-of-concept, (ii) non-exclusively license the TSDT platform itself to large pharma partners, and (iii) fund R&D partly through sales of research reagents. In 2017 the company reported revenue of KRW 2.7 bn, operating loss of KRW 3.4 bn and net loss of KRW 3.5 bn, with reagent sales described as a source of self-generated R&D funding (BioSpectator, Sept 2018). In 2016 revenue was KRW 1.3 bn, which management attributed to licensing-related activity (Kormedi report on MJFF grant). **What the company actually became.** From November 2021 the revenue base changed fundamentally. Cellivery acquired 100% of Ajin Clean, a wet-tissue and hygiene-products maker founded in 1991, for KRW 14.9 bn, injected a further KRW 14.0 bn of capital, and renamed it Cellivery Living & Health (BizWatch, 18 Jul 2022; Economist Korea, 5 Apr 2023). From FY2022, essentially all consolidated revenue came from this consumer subsidiary (cosmetics, hygiene and lifestyle goods). The parent company's separate revenue was zero in FY2023 and again zero in FY2024 (Dailypharm, 5 Jun 2024; MTN, 21 Feb 2025). **Revenue mix (independent characterisation).** **Value-chain position.** Pre-2021: discovery and preclinical research, with manufacturing (CMC) and all GLP toxicology and clinical work outsourced to CROs/CMOs in the US, Europe and Asia (Covance/Labcorp, Southern Research, OPIS, KBI). Post-2021: additionally a domestic consumer-goods manufacturer and retailer through the subsidiary. **Customer types and end-markets.** Intended: global pharmaceutical companies as licensees (neurology, oncology, immunology/infectious disease). Actual: academic and industrial labs (reagents) and Korean retail consumers (Living & Health products via department stores, duty-free and a flagship store; the premium brand later withdrew from department-store and duty-free channels per Economist Korea, Apr 2023). **Company's own description.** The latest annual report language is not available in the sources reviewed. Third-party aggregators summarise the company as developing protein, small-molecule, antibody and vaccine drugs primarily for South Korea, holding US-registered patents, and operating Cellivery Living & Health in beauty and health since January 2022 (roic.ai company profile). **Current operating state (2025–2026).** Following delisting, the company is controlled by shareholders who removed the founder. Public reporting in 2026 focuses on the criminal case against former management rather than on any resumed R&D. No active clinical programme, partnership or product revenue at parent level has been publicly disclosed since 2023.

Revenue$0.0B
Employees9
Market CapN/A
Founded2014
United States, North America
Cellid

Cellid, Co., Ltd.

Premium
Information Technology

Cellid is a Korean clinical-stage immunotherapy company built on CeliVax. CeliVax is a cell-based cancer vaccine platform that loads tumour antigens into a patient's own B cells and monocytes using an adenoviral vector, and adds the NKT-cell adjuvant α-galactosylceramide. The company listed on KOSDAQ in 2019 on the strength of its HPV-cancer vaccine BVAC-C. From 2020 it redirected most of its capital into an adenovirus-vector COVID-19 vaccine. In June 2026 that vaccine (AdCLD-CoV19-1 OMI) failed to show non-inferiority to Pfizer's Comirnaty in a global Phase 3 trial. Cellid has had no meaningful drug revenue since listing. Its reported revenue now comes almost entirely from ForBaker, a bakery e-commerce business it absorbed in 2024 to meet KOSDAQ revenue-maintenance thresholds. With cash falling, short-term borrowings rising and its lead asset impaired, Cellid agreed in September 2026 to cede control to Huniverse Global. Huniverse is a medical-IT company backed by Korea University's technology holding company and plans data-driven personalised cancer vaccines. --- ### What the company does Cellid runs three activities. The first, R&D, is its reason for existing. The second produces nearly all of its revenue. The third is small and still developing. 1. **Biopharmaceutical R&D (core, pre-revenue).** - CeliVax-based therapeutic cancer vaccines (the BVAC family). - Adenovirus-vector prophylactic vaccines, mainly COVID-19. - The platform uses autologous B cells and monocytes as antigen-presenting cells. Antigen genes are delivered by a replication-incompetent adenovirus, and α-galactosylceramide is added to activate NKT cells. - Manufacturing takes about one day per batch (company disclosure at IPO, 2019). 2. **E-commerce / bakery (revenue-generating).** This is the ForBaker business, acquired in March 2024 for about KRW 12 and merged by absorption in 2024. It produced 91.4% of FY2024 revenue and about 99.97% of FY2025 revenue. 3. **Contract manufacturing / CDMO services (emerging, immaterial).** - GMP production and quality-analysis services for viral vectors and cell and gene therapies, run from the Seongnam GMP centre. - CMO revenue was KRW 3.15 in Q1 2024 and only KRW 0.03 in Q1 2025. - A June 2025 MOU with AltiCure led to a stability-testing and product-storage contract on 2 Sep 2026. The contract value was not disclosed. ### Business and revenue model | Revenue type | Status | Evidence | |---|---|---| | Product sales (drugs) | None. No product has been approved. | Revenue was KRW 0 in FY2023 (DART) | | Licensing / milestones | Historic upfront payments only: KRW 10 from LG Chem (2021) and an early US-only BVAC-C licence to NeoImmuneTech (2014). Milestones of up to KRW 1,825 from LG Chem are contingent. | Company release, 26 May 2021 | | Contract manufacturing (CMO/CDMO) | Sporadic and small | 8.6% of FY2024 revenue; 0.2% of Q1 2025 revenue | | Merchandise (bakery e-commerce) | About 100% of current revenue | FY2025 revenue of KRW 88.4, almost all e-commerce | | Subscription | None | — | ### Value-chain position and customers Cellid sits at the discovery, translational and clinical-development stages of the biopharma value chain. It also has in-house GMP manufacturing for clinical supply. Its intended end customers are: - Oncology patients and hospitals, for HPV-positive cervical, head-and-neck and other cancers. - National immunisation and booster programmes, for COVID-19. The company had said it would target developing countries with a lower-cost adenoviral vaccine. - Biotech developers that need viral-vector CDMO services. The bakery segment sells to consumers through online channels. ### Company self-description vs. independent characterisation **Company self-description (paraphrased):** a "leader in cell-based immunotherapy" that develops immunotherapeutic vaccines for cancer and infectious diseases on its proprietary CeliVax platform. **Independent characterisation:** Cellid is a capital-constrained, single-platform biotech whose most advanced programme has failed. It has relied on four equity raises in four years (2023–2026), a bakery acquisition to stay above KOSDAQ revenue thresholds, and now a change of control. What remains of scientific value is concentrated in three areas: - BVAC-C plus durvalumab in second-line cervical cancer. - BVAC-E6E7 in HPV-positive head-and-neck cancer. - The LG Chem-partnered neoantigen programme (BVAC-Neo), which is still preclinical.

RevenueN/A
Employees49
Market CapN/A
Founded2006
United States, North America
Celemics

Celemics, Inc.

Premium
Information Technology

Celemics is a Seoul-based developer and manufacturer of hybridization-capture target enrichment reagents for next-generation sequencing (NGS), built on proprietary molecular-cloning (MSSIC™) and molecular-barcoding (BTSeq™) technology developed by its academic founders. It is one of a small number of companies globally — six, by the company's own IPO-era claim — capable of manufacturing target capture probe kits, and it describes itself as the only such manufacturer in Europe, Asia and the Middle East. Its revenue base remains very small (KRW 5.8 bn in FY2025) and has contracted since a FY2022 peak, with persistent operating losses since listing. In 2026 the company changed controlling shareholder, raised roughly KRW 31 bn through rights issues and convertible bonds, and pivoted toward a royalty-plus-kit model for US clinical oncology testing via a three-year, minimum-USD 7.225M agreement with San Diego CLIA lab Achieve Diagnostics. It is, in effect, a technology-rich but commercially sub-scale reagent maker attempting a clinical-market and M&A-led reset. --- ### What the company does Celemics designs, manufactures and sells reagents and services used in targeted NGS. Its core product is the target capture (target enrichment) kit: a pool of synthetic DNA/RNA probes that hybridize to selected regions of a genome so that only those regions are sequenced. Targeted sequencing is cheaper and deeper than whole-genome sequencing, and is the workhorse method for clinical cancer panels, hereditary-disease panels, exome sequencing and pathogen surveillance. The company's technology stack, as described in its IPO materials and subsequent disclosures: **MSSIC™ (Massively Separated and Sequence-Identified Cloning):** a high-throughput molecular cloning platform combining nano-optical techniques with NGS to isolate, propagate and sequence-verify very large numbers of DNA molecules at low cost. This is the foundational "DNA materials" technology from which probe pools are produced (Dealsite, 30 Jul 2020; Biospectator, 2020). **Probe design and rebalancing:** after a pre-production pilot, Celemics rebalances individual probe concentrations to improve coverage uniformity, including in GC-rich and homologous regions that competitors are said to mask (GenomeWeb, US subsidiary launch; Medical-XPRT product page; Funakoshi distributor brochure). **BTSeq™ (Barcode-Tagged Sequencing):** a unique-molecular-identifier (UMI) approach with error-removal algorithms, enabling accurate reads of long fragments (>1 kbp) and detection of rare variants below 1% variant allele frequency — relevant to liquid biopsy and minimal residual disease (Biospectator, 2020; Korea University TLO page). **Bioinformatics:** Celemics Analysis Service (CAS), an end-to-end pipeline from FASTQ to annotated variants, and a "Sample-to-Report" offering run with Strand Life Sciences' StrandOmics (India) and the BlueBee cloud platform (Netherlands) (KU TLO page). ### Business and revenue model | Revenue stream | Description | Weight | Source | |---|---|---|---| | Target capture kits (product) | Custom and catalogue enrichment panels, whole exome, accessories (library prep, beads, enzymes) | ~85% of Q2 2026 revenue | Butler (DART-derived) | | NGS services | Sequencing, bioinformatics, custom assay development, infectious-disease whole-genome sequencing for public agencies | ~15% of Q2 2026 revenue | Butler; KU TLO | | Licensing / royalty (new from Q4 2026) | 20% royalty on Achieve Diagnostics' US clinical test net sales using five Celemics panels, plus minimum kit purchases | Not yet reported in revenue | MoneyToday, 4 Sep 2026; Hankyung, 1 Sep 2026 | | Subscription | None identified | — | — | Historically the model has been a classic research-use-only (RUO) reagent business: one-off and repeat kit sales to hospitals, reference laboratories, pharmaceutical companies, seed/breeding companies and research institutes (Asia Economy, Aug 2024). The 2026 Achieve agreement introduces the first disclosed volume-linked royalty stream tied to reimbursed US clinical testing. ### Value-chain position Celemics sits in the upstream consumables layer of the NGS value chain: it supplies the enrichment chemistry that sits between sample preparation (DNA extraction, library preparation) and sequencing instruments (dominated by Illumina, with MGI, Thermo Fisher and PacBio as alternatives). Its kits are stated to be compatible with Illumina, Thermo Fisher, Pacific Biosciences and MGI instruments (Medical-XPRT product page), which positions it as an instrument-agnostic second source. Downstream, it partially integrates into services (sequencing and bioinformatics) and, from 2026, into clinical testing economics via royalties. ### Customer types and end-markets Customers named or described in public sources: hospitals, contract testing labs, pharmaceutical companies, seed companies, research institutes (Asia Economy, Aug 2024); the Korea Disease Control and Prevention Agency (KDCA) for 2025–2026 infectious-disease surveillance; National Cancer Center Korea (collaboration); distributors and partners in China (Sangon Biotech; earlier Tsingke via distributor Forcula), India (Imperial Life Science), Japan (Funakoshi) and the US (Achieve Diagnostics; MedCare Partners Health Plan of Texas MOU). End-markets: oncology (hereditary and somatic), rare/inherited disease (clinical exome), pharmacogenomics, infectious disease and pathogen surveillance, liquid biopsy, immune-repertoire/antibody discovery, agrigenomics/breeding, microbiome and synthetic biology. ### Company's own description vs. independent characterization *Company description (paraphrased from 2026 press materials and IR):* an NGS specialist operating a platform business built on MSSIC since 2010, applied across medicine, drug development, microbiome, synthetic biology and breeding, and the self-producing target capture kit maker in Europe, Asia and the Middle East; in 2026 it framed its strategy as a "two-track" of strengthening the NGS core while investing in new businesses (VentureSquare, 8 Jun 2026). *Independent characterization:* Celemics is a technically credible but commercially sub-scale reagent company. Six years after listing it has never generated an operating profit, its revenue (KRW 5.8 bn in FY2025) is lower than in FY2021, and it missed its IPO-era revenue projections by roughly 90% (Dealsite, 24 Oct 2025). Its only profitable year (FY2024) was driven entirely by a fair-value gain on a minority stake in IMBdx. The 2026 change of control, aggressive equity/CB issuance, an earmarked ~KRW 11.5 bn for acquiring "other companies' securities", and an above-market third-party issue to an entity named C&P point to a balance-sheet and strategic reset whose end-state is not yet disclosed. The Achieve contract is the first commercial evidence that the core technology can be monetized at scale in the US, but it is a minimum commitment from a single counterparty that had no prior NGS testing capability.

Revenue$0.0B
Employees40
Market Cap$0.1B
Founded2010
United States, North America
Cayman

Cayman Golden Century Wheel Group Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Cayman Golden Century Wheel Group Limited (Korean: 케이만금세기차륜집단유한공사) | [S1][S20] | | Trading / short name | Golden Century (골든센츄리) | [S1] | | Proposed former/alternate name | Shareholders were asked in March 2023 to approve renaming the company "ESOPP Mobilities" (이솝 모빌리티스) | [S14][S23] | | Origin of operating business | Yangzhou Golden Century Wheel Manufacturing Co., Ltd. (양주금세기차륜제조유한공사), founded May 2004 | [S20][S27] | | Holding company incorporation | Cayman Islands, September 2014 (created as the offshore listing vehicle because Korean rules did not permit direct listing of the PRC operating entity) | [S20][S21][S27] | | Intermediate holding | Hong Kong Golden Century Wheel Group Ltd., established December 2011 | [S27] | | Registered headquarters | Cayman Islands (registered office address not publicly disclosed in sources reviewed) | [S21] | | Korean office | Seoul, Gangnam-gu (shareholder meetings held at the "head office" in Gangnam in 2024) | [S17] | | Principal operations | Yangzhou (Jiangsu Province) and Luoyang (Henan Province), PRC | [S8][S27] | | Exchange / ticker | KOSDAQ (Korea Exchange), code 900280 — delisted 8 January 2025 | [S23] | | IPO date | 19 October 2016 | [S1] | | IPO price | KRW 3,500 per share | [S2] | | ISIN / CUSIP | Not publicly disclosed in sources reviewed (no CUSIP; Korean-listed foreign issuer) | — | | Fiscal year end | 31 December | [S19] | | Reporting currency | Consolidated accounts reported to the Korean market in KRW; underlying operations in CNY | [S9][S19] | | Shares outstanding (last listed) | 205,404,288 (April 2024) | [S21] | | Employees (latest and 3-year trend) | Not publicly disclosed in sources reviewed | — | | Auditor (FY2023) | Shinhan Accounting Corporation (신한회계법인) — issued disclaimer of opinion | [S20] | | Market capitalization (current) | Not applicable — delisted; last pre-suspension reference: ~KRW 21.2 bn at KRW 104/share (9 April 2024) | [S21] | | Website | Korean IR site: goldencentury.co.kr | [S27] | | Controlling shareholder | Zhu Chenghua (주승화), founder, CEO and largest shareholder — 24.74% at H1 2022, 11.84% (24,317,193 shares) by 2023–2024 | [S13][S18][S21] | Golden Century is a Cayman-domiciled holding company whose operating subsidiaries in Yangzhou and Luoyang, China, manufacture steel wheels for medium, large and extra-large agricultural tractors, agricultural tyres, and — since August 2020 — complete tractors sold under the "Dimachi" name. At its 2016 KOSDAQ IPO it presented itself as China's only producer of both wheels and tyres for medium/large tractors and as market leader in the extra-large tractor wheel niche, supplying China's leading tractor OEMs including First Tractor (YTO), Changzhou Dongfeng, Jiangsu World and Shandong Shifeng. The business delivered operating margins above 20% through 2019–2021, but revenue fell sharply in 2022–2023 as the move into complete tractors alienated wheel customers. In 2023 an unexplained CNY 586 million "R&D" charge, a regulatory market-manipulation referral, and failed capital raises preceded an auditor's disclaimer of opinion. The shares were delisted from KOSDAQ in January 2025; the entity is now effectively a non-transparent private PRC manufacturer. --- ### What the Company Does Golden Century is a vertically oriented manufacturer of running-gear components for agricultural tractors. Its core product is the steel wheel (rim and disc assembly) for medium-horsepower, large-horsepower and extra-large-horsepower wheeled tractors. It also produced agricultural tractor tyres through its Luoyang tyre subsidiary, which allowed it to market itself as the only Chinese producer offering both the wheel and the tyre for medium/large tractors [S1][S4]. From August 2020 it expanded downstream into complete tractor manufacturing under the "Dimachi" (디마치) brand [S12]. A third, non-core revenue stream became material in later years: sales of steel scrap generated during wheel fabrication. A 2024 analyst-blog summary of the company's disclosures put scrap and other sales at roughly 30% of revenue, alongside about 45% from wheels and about 25% from tractors [S21]. The company's own Q3 2023 disclosure showed wheels at 45.3% and tractors at 24.9% of revenue, consistent with that split [S18]. ### Business Model and Revenue Model | Dimension | Characterization | Source / basis | |---|---|---| | Revenue model | Product sales (B2B, OEM supply); no material service, subscription or licensing revenue disclosed | [S4][S21] | | Pricing | Contract-based supply to tractor OEMs; per-unit pricing not disclosed | [S7] | | Customer type | Chinese tractor OEMs (wheels/tyres); agricultural end users and distributors (complete tractors); trading companies/exporters | [S4][S7][S21] | | Value chain position | Tier-1 component supplier (wheels/tyres) moving to OEM (complete tractors) — creating channel conflict with its own customers | [S19] | | End-market | Chinese agricultural mechanization, specifically the medium/large/extra-large tractor segment | [S4][S12] | | Capital intensity | High — steel forming/welding lines, tyre production, and a planned large-scale tractor plant (KRW 223.8 bn announced April 2021) | [S18] | ### Company Self-Description The company's Korean website described Golden Century as a leading enterprise in global agricultural modernization that began with tractor wheel and tyre production in May 2004, extended into complete tractor production and sales, and held the No.1 position in China's agricultural machinery wheel field; it stated an intention to diversify its product line and expand overseas to become a global company [S27]. At listing it claimed approximately 50% supply share of medium/large tractor wheels, 55% of extra-large tractor wheels, and 100% of export tractor wheels in China (company-stated figures) [S3]. ### Independent Characterization On the evidence available, Golden Century was a profitable mid-sized Chinese metal-fabrication business between 2016 and 2021, with reported operating margins of roughly 22–27%, unusually high for a steel wheel fabricator and consistently at the top of what would be expected for the category. From 2022 onwards the investment case deteriorated across three dimensions simultaneously: 1. **Strategic error:** Entering complete-tractor assembly put the company in direct competition with the OEMs that bought its wheels. Management explicitly attributed the FY2023 revenue decline to reduced orders from former wheel customers after the tractor launch [S19]. 2. **Governance failure:** Korean regulators referred executives to prosecutors over manipulation of the share price during the 2017–2018 rights offering [S16]; a CNY 586 million "R&D" expense in Q3 2023 left no corresponding asset on the balance sheet [S18]; and the FY2023 auditor could not obtain sufficient evidence over R&D, patent purchases, cash, borrowings and possible off-balance-sheet liabilities [S20]. 3. **Capital-markets drift:** A succession of announced but withdrawn convertible bonds, third-party share placements, a proposed rename to a secondary-battery "mobility" company, and changes of control proposals in 2022–2024 [S13][S14][S17][S26] are characteristic of thinly traded KOSDAQ shells rather than of an operating industrial company. The entity should be understood today as a delisted, non-reporting PRC manufacturer with an unresolved question over the existence and location of the cash that was on its balance sheet in 2022.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2004
Cayman Islands
Caxton

Caxton and CTP Publishers and Printers Limited

Premium
Information Technology

Caxton is a South African, family-controlled, cash-rich industrial-media group that has evolved from a newspaper publisher and printer into a business where packaging and stationery now generate the majority of revenue and profit. It operates two reporting segments: Publishing, Printing and Distribution (local community newspapers, The Citizen daily, retail-insert and newspaper printing, book and magazine printing, and the Cognition activation/research business) and Packaging and Stationery (labels, folding cartons, flexible packaging, cigarette packaging, beverage cartons, corrugated, and stationery brands such as Flip File and Tidy Files). Its defining financial trait is an ungeared balance sheet carrying more than R3.0 billion of cash plus a 34.9% stake in JSE-listed Mpact Limited. The group trades at roughly half of net asset value, with the market ascribing little value to its operating businesses. Strategy is conservative and capital-disciplined, led by an 82-year-old founder-CEO who has controlled the company since 1977. --- **Company's own description.** Caxton's integrated annual reports describe the group as a major publisher and printer, and manufacturer of packaging material in South Africa, driven by excellence across publishing, printing and manufacturing, with the aim of delivering quality products to clients and superior returns to shareholders while contributing to a democratic and prosperous South Africa (IAR 2025, cover statement; paraphrased except for the core descriptor). **What the company does.** The group runs two operating segments plus an "Other" segment for treasury and investment activity (IAR 2025; interim results H1 FY2026): 1. **Publishing, Printing and Distribution (PPD)** — publishes approximately 115–120 local newspaper titles (the 2024 investor presentation cites 120 local titles; a 2024 market report cites 115 local newspapers and 58 local news websites sold through Caxton's Spark Media sales house), the national daily *The Citizen* and its website, and operates seven newspaper printing operations, two commercial (heatset web and gravure) printing plants in Johannesburg and Durban, and a book and magazine printing operation in the Western Cape. It also includes Cognition (activation, incentives and research), which was delisted and became wholly owned in June 2024. 2. **Packaging and Stationery (P&S)** — manufactures labels (long-run beer labels in Gauteng; short- and medium-run wine, spirits, cider, beverage and can labels in the Western Cape), folding cartons (quick-service restaurant (QSR) buckets and cups, FMCG, frozen food, pet food, agriculture), cigarette packaging, beverage carton baskets (with Graphic Packaging International), flexible packaging (bag-in-box wine bladders, laminates, beverage labels, hygiene films, tyre-liner film), corrugated board/boxes, and stationery (Flip File display books, Donau files, Tidy Files and SFS filing brands, diaries and journals, Grafton craft paper, Premier scholastic books) (2024 investor presentation; IAR 2025; interim results H1 FY2026). 3. **Other** — dividends (principally from Mpact), interest on cash balances, intergroup rent, head-office costs and, in FY2023–FY2024, insurance receipts relating to the April 2022 Durban floods (FY2024 results SENS). **Business and revenue model.** The revenue model is predominantly product/manufacturing revenue (packaging, labels, stationery, commercial and book printing), supplemented by advertising revenue (national retail and local SME advertising in print and, increasingly, digital), circulation revenue (The Citizen), services revenue (Cognition incentives and research), and investment income (interest and dividends reported below operating profit as net finance income). Caxton does not disclose a revenue split by type (product vs. advertising vs. services); the segment split is the closest proxy, with P&S at 55.7% of FY2025 revenue (IAR 2025 segment data via H1 FY2026 interim comparatives). There is no subscription or licensing model of significance disclosed. **Value-chain position.** Caxton is a converter and publisher, not a primary paper producer. It buys newsprint, coated paper, cartonboard, label stock, films and inks (partly imported), converts them into printed and packaging products, and distributes newspapers through its own distribution operations. Its upstream exposure became more import-dependent after Mpact's Springs mill — South Africa's only domestic cartonboard producer — ceased production in 2026; Caxton reported that it migrated cartonboard supply to overseas sources without interruption (FY2026 results SENS; Mpact FY2025 results). **Customer types and end-markets.** National grocery and liquor retailers (advertising inserts, brochures and newspaper advertising; grocery is the largest publishing customer segment per H1 FY2026 interim), local SMEs (community newspaper advertising), government and legal-notice advertisers (The Citizen), education publishers and the Department of Basic Education supply chain (textbooks), brewers and beverage companies (beer, cider, spirits, wine and soft-drink labels; beer cartons), tobacco manufacturers (British American Tobacco is a named customer), QSR chains, FMCG and frozen-food producers (including Namibian fishing), wine producers (bag-in-box bladders), and wholesale/retail stationery channels (IAR 2025; H1 FY2026 interim). **Independent characterisation.** Economically, Caxton is best understood as three assets: (i) a mid-sized, well-capitalised South African packaging converter with steady double-digit EBITDA margins; (ii) a cash-generative but structurally declining print-media and printing business that is being managed for cash; and (iii) an investment holding layer consisting of over R3 billion in cash and a non-controlling 34.9% stake in Mpact. The investment layer represents a large share of net asset value, and capital-allocation decisions about that layer are, in practice, more important to shareholder value than incremental operating performance.

Revenue$0.4B
Employees4
Market CapN/A
Founded1902
United States, North America
CastecKorea

Castec Korea Co., Ltd.

Premium
Information Technology

Castec Korea is a Busan-based ferrous casting and machining specialist whose roots lie in GoldStar/LG Electronics' foundry operations. Its core franchise is the supply of cast and machined turbine housings and center (bearing) housings to global turbocharger module makers — historically Honeywell Turbo (now Garrett Motion), BorgWarner and Korean turbo assemblers — complemented by an electronics-parts business producing compressor castings (crankshafts, cylinders, cylinder blocks, scrolls, mainframes) for air-conditioner and refrigerator compressors, plus chassis/brake and hydraulic castings. In Q2 2026, automotive parts represented about 78% of sales and electronics parts about 22%. The company operates in Korea, China and Vietnam, with a European sales presence in Romania. Financially it is a distressed small-cap: six consecutive years of operating losses (2020–2025), interest coverage below 1x since at least 2020, a market capitalisation of roughly KRW 29 bn against net debt of ~KRW 77 bn, and an unresolved, litigated contest for corporate control. --- ### What the company does Castec Korea manufactures cast-iron and heat-resistant cast components through sand-casting and precision machining, and sells them predominantly to Tier-1 module makers rather than vehicle OEMs. The S&P Global business description (as published by Yahoo Finance/StockAnalysis, 2026) lists four product families: 1. **Turbocharger parts** — turbine housings and center housings (also called bearing housings), the latter connecting turbine and compressor stages and carrying the rotating assembly. 2. **Other automotive parts** — calipers, carriers, balance shafts, differential carriers, hubs, knuckles, brake rotors and tensioners. 3. **Hydraulic and undercarriage parts** — spindles, hubs, covers, carriers, cylinder blocks and rear flanges, plus undercarriage system parts (consistent with Craft's description of "driving device parts for heavy industry"). 4. **Compressor parts (electronics segment)** — crankshafts, cylinder blocks, cylinders, flange tops, mainframes, scrolls, shafts, thrust holders and wheel cylinders used in electric compressors for home appliances. The Komachine profile (2025–2026) describes the company as supplying "eco-friendly, high-efficiency" turbocharger components (turbine housings, center housings and impellers) and electronic compressor parts from a production network in Korea (Mieum, Macheon, Changwon), China (Suzhou, Qinhuangdao), Vietnam (Castec Vina, Ben Cat) and a European branch in Romania. ### Company's own characterisation The latest annual report text could not be retrieved directly. Secondary reporting of DART filings (The Value News, July 2017) states that the company's registered business purposes comprise casting manufacture and sales, casting technology consulting, casting equipment manufacture and sale, machining, and leasing — i.e., it defines itself as a foundry-and-machining business serving electronics and automotive customers. ### Business and revenue model **Revenue model:** Overwhelmingly product sales (build-to-print castings, often machined). No subscription, licensing or service revenue has been disclosed. Leasing is a registered purpose but no material rental income has been reported. **Pricing:** Contract/part-number pricing with Tier-1 customers; multi-year supply agreements are disclosed when material (e.g., Honeywell Technologies SARL turbine/center housing contract valid Jan 2019–Dec 2026, expected sales KRW 41.87 bn — MarkLines). **Value-chain position:** Tier-2 supplier. Raw materials (pig iron, steel scrap, ferro-alloys, nickel for heat-resistant grades) → Castec (melting, moulding, casting, heat treatment, machining) → Tier-1 turbo module maker (Garrett, BorgWarner, Korean turbo assemblers) or compressor maker (electronics) → vehicle OEM / appliance OEM. **Customer types:** Turbocharger module makers (Honeywell/Garrett, BorgWarner, and historically Seohan Warner Turbo Systems and Keyang Precision — The Value News, 2017), compressor/appliance makers (the electronics business originated inside LG Electronics), and industrial/hydraulic equipment makers. **End-markets:** Light vehicles (gasoline and diesel turbocharged engines, increasingly hybrids), commercial vehicles, construction/heavy machinery hydraulics, and home-appliance compressors (air conditioners, refrigerators). ### Independent characterisation Castec Korea is a sub-scale, capital-intensive Tier-2 foundry with high customer concentration and structurally thin gross margins (–0.6% to 5.6% in FY2021–FY2025). Its competitive asset is qualified status on turbine/center-housing programmes at global turbo makers — a qualification barrier that protects volumes but not pricing. The company has spent 2024–2026 shrinking its asset base (sale of the Mieum land and buildings, an attempted Sasang plant sale, disposal of Suzhou subsidiary assets), shifting production weight toward Vietnam (the Vietnamese subsidiary's sales growth was cited by management as the driver of the FY2025 operating-loss improvement), and refinancing a short-term-heavy debt stack. Simultaneously, a shareholder group led by director Lee Hak-chul has built a 38.01% co-holding position and is litigating against resolutions of the incumbent management's shareholders' meetings. The investment case is therefore primarily a restructuring/control-contest situation rather than an operating-growth story.

Revenue$0.1B
Employees137
Market CapN/A
FoundedN/A
Busan, South Korea
Carelabs

Carelabs Co., Ltd.

Premium
Information Technology

Carelabs is a Seoul-based, KOSDAQ-listed digital health and medical-aesthetics platform group controlled since January 2023 by Wonik Holdings, the holding company of a mid-sized Korean semiconductor and battery-equipment conglomerate. Its economic engine today is Babitalk, a medical-beauty information and review platform that generated about KRW 36.8 bn of revenue and KRW 7.3 bn of operating profit in FY2025 and is being absorbed into the parent in December 2026. Around it sit a shrinking parent-level B2B services business (performance marketing for clinics, hospital CRM software, smart-hospital kiosks, medical recruiting), a profitable pharmacy-software subsidiary (EDB), a structurally loss-making telemedicine and booking app (Goodoc), and early-stage bets on oncology information (Heal-O) and senior care. Consolidated revenue has drifted from KRW 93.9 bn (FY2021) to KRW 81.7 bn (FY2025) with recurring operating losses since FY2022. The equity story rests on Babitalk's inbound medical-tourism opportunity and Korea's December 2026 telemedicine legalisation, offset by governance, scale and liquidity concerns. --- ### Company's own description In its corporate materials Carelabs presents itself as a healthcare and beauty-care platform company for everyone, providing comprehensive healthcare IT services that include clinic information services, clinic customer-management software and digital-marketing solutions [S1][S3]. Its IR materials and press releases describe a "digital healthcare value chain" connecting patients, medical staff, hospitals and pharmacies through the parent and three subsidiaries (Goodoc, Babitalk, EDB) [S17][S25]. At the March 2026 AGM management framed 2026 as a turnaround year built on entry into senior care, AI-enhanced services and a "One CareLabs" integration concept [S22]. ### Independent characterisation Carelabs is best understood as a holding-style portfolio of five distinct businesses with very different economics: 1. **Medical-aesthetics marketplace (Babitalk)** — a two-sided platform monetised primarily through advertising and performance fees paid by plastic-surgery, dermatology and aesthetic clinics. It is the only clearly profitable, growing engine (FY2025 revenue KRW 36.8 bn, operating profit KRW 7.3 bn, ~3,300 hospital/doctor network, 10 million cumulative downloads) [S29][S17]. 2. **Parent-level B2B services for clinics** — performance/digital-marketing agency services, hospital CRM software ("Uno CRM"/Care CRM), smart-hospital solutions (kiosk payment, certificate issuance, queue management, RFID, QR), and the Medijob/Yobosarang recruiting platforms [S3][S25]. Parent-only revenue fell from KRW 41.0 bn (FY2024) to KRW 33.8 bn (FY2025) and a further 36.2% YoY in Q1 2026 [S1][S12]. 3. **Pharmacy software (EDB, 51% owned)** — QR-code prescription-security systems and pharmacy claims software; Q1 2026 revenue KRW 3.5 bn (+24% YoY) with operating profit up 255% [S7][S17]. 4. **Consumer healthcare access app (Goodoc, 88.74% owned)** — clinic search, booking and walk-in registration, telemedicine and prescription transfer. Revenue collapsed from about KRW 12.1 bn (2021) to KRW 1.0 bn (2024 and 2025); the entity has been in full capital impairment since end-2021 [S7]. 5. **New bets** — Heal-O oncology-journey platform (launched Aug 2025) and a planned senior-care facility on land acquired in Seoul's Godeok-Gangil district (2025) [S26][S30]. ### Revenue model mix | Revenue type | Main business lines | Characterisation | |---|---|---| | Advertising / performance fees from clinics | Babitalk, Goodoc, Heal-O (potential) | Platform/marketplace revenue; dominant and highest margin | | Agency / service fees | Parent digital-marketing division | Project and performance-based services; declining | | Software licences / subscriptions | Hospital CRM, EDB pharmacy software, smart-hospital solutions | Recurring B2B SaaS-like revenue | | Hardware-linked solutions | Smart-hospital kiosks, tablets | Equipment plus service; minor cost of sales | | Recruitment fees | Medijob, Yobosarang | Job-posting / matching fees | Exact revenue split by revenue type is not publicly disclosed in sources reviewed. Aggregator data based on Q2 2026 filings put the reported segment mix at roughly 50% healthcare media platforms, 26% solutions and 24% marketing [S5]. Cost of revenue is negligible (KRW 0.17–0.94 bn per quarter in 2025–26) because the company presents most expenses within SG&A [S13]. ### Value-chain position, customers and end markets Carelabs sits in the demand-generation and workflow layer between consumers and providers. Paying customers are overwhelmingly B2B: private plastic-surgery and dermatology clinics (Babitalk), primary-care clinics and hospitals (Goodoc, CRM, smart hospital), pharmacies (EDB), and healthcare employers including long-term-care institutions (Medijob, Yobosarang). Consumers use most services free of charge. End markets are Korean medical aesthetics, inbound medical tourism (initially Japan), primary care access and telemedicine, pharmacy IT, healthcare staffing and, prospectively, senior care.

Revenue$0.1B
Employees123
Market CapN/A
Founded2012
United States, North America
CalgroM3

Calgro M3 Holdings Limited

Premium
Information Technology

Calgro M3 is a South African developer that focuses on affordable housing and also owns a private cemetery business. It operates two segments. The first, Residential Property Development, designs, services and sells mixed-typology "integrated" housing estates, from state-subsidised units to bonded open-market homes, mostly in Gauteng and the Western Cape. The second, Memorial Parks, owns and manages six private burial parks. The company has historically acted as a turnkey developer: it controls land, town planning and bulk infrastructure, and outsources construction. Its competitive edge rests on long-dated land banks bought at low historical cost and on experience working alongside municipalities. The investment case now depends on the 20,000-unit Bankenveld District City (BDC) project near Sandton, which is being developed with Eris Property Group. Memorial Parks provides annuity-style cash flow that covers group overheads. The shares trade at about 0.23× net asset value, which reflects market scepticism about how quickly the balance sheet will convert to cash. --- ### Company's own description IR2026 describes Calgro M3 as a property and property-related investment company that specialises in two activities: developing Integrated Residential Developments, and developing and managing Memorial Parks. Its housing developments combine subsidised, social, First Home Finance (FHF), affordable rental and affordable ownership typologies. Schooling and communal facilities are included so that households can move up the housing ladder without leaving the community, while staying close to jobs. The group's mantra is "Building legacies. Changing lives." ### Business model and value chain position **Residential Property Development.** Calgro M3 runs the front end of the development value chain: 1. Project identification and due diligence 2. Land acquisition 3. Township establishment and planning approvals 4. Planning, design and installation of bulk and link infrastructure 5. Top-structure design 6. Marketing and sales 7. Transfer to end-users Infrastructure installation and top-structure construction are outsourced to contractors (FYP2023 appendix; IR2026 value creation diagram). Management's view is that controlling the land and the development rights is what "traps margin" in the business. This control also lets the company shift its product mix between market segments as economic conditions change. **Memorial Parks.** The group identifies and acquires land, develops landscaping and infrastructure through outsourced contractors, and sells burial rights. Customers can pay in cash or through a 0% lay-by plan of up to 24 months. The group then provides interment services and perpetual maintenance. ### Revenue model | Revenue stream | Recognition characteristics | Source | |---|---|---| | Sale of completed residential units (open market, sectional and full title) | Point-in-time, on transfer | IR2026 | | Construction contracts with public-sector counterparties (subsidised BNG/CRU units, infrastructure) | Over time (milestone-based) | IR2026 "Where to from here" | | Serviced land / bulk sales to investors and social housing institutions | Point-in-time | FYP2023 revenue disaggregation | | Infrastructure installation revenue | Over time | FYP2023 | | Memorial Parks burial rights | Point-in-time, on receipt of full payment; lay-bys are recognised only when fully paid | FY2025 SENS | | Memorial Parks burial (interment) services | Deferred, then recognised when the interment is performed (policy restated FY2025) | FY2025 SENS | | Other income (e.g., bond origination commissions) | Not separately quantified in sources retrieved; FY2024 other income rose 28% on higher bond commissions | FY2024 SENS | Calgro M3 does not sell products, subscriptions or licences in the conventional sense. Revenue comes from the following sources: The FY2023 residential revenue split was: open-market units 54%, infrastructure 31%, government-funded units 8% and land sales 7% (FYP2023, chart reading). A comparable split for FY2025–FY2026 was not disclosed in the sources retrieved. ### Customer types and end-markets **Public sector:** municipalities and provincial housing departments buying fully subsidised BNG ("Breaking New Ground", the successor to RDP housing) and CRU (council rental) units. Target household income is below about R3,500 to R7,500 per month (IR2026 housing segment table). **Social housing institutions:** regulated subsidised rentals, for households earning roughly R7,501–R22,000 per month. - **First-time buyers using FHF subsidies, and private affordable-rental landlords:** households earning below R38,500 per month. **Bonded open-market buyers:** units up to roughly R900,000, aimed at households earning above R22,000 per month. Separately, a mid-to-high tail runs to above R3 million (for example 32-on-Pine, priced from about R4.2 million). **Property investors / bulk buyers:** management increasingly targets bulk sales to investors. At the FY2026 results presentation, the CEO said the company aims to sell units in bulk because end-users will take longer to recover from macroeconomic pressure (Engineering News, 18 May 2026). **Student accommodation:** a 136-bed project for a private investor and a 630-bed development for the University of the Western Cape at Belhar (IR2026). **Memorial Parks customers:** households across a wide LSM (living standards measure) range. Products run from berm graves to family estates. ### Independent characterisation Calgro M3 is best understood as a land-and-infrastructure merchant developer. Its earnings are driven by the timing of unit transfers and infrastructure milestones, not by a recurring rental base. Three structural features define it: 1. **Capital intensity at the front of each project.** Bulk infrastructure has to be funded well ahead of sales. This is visible in construction contracts of ZAR 2.1 bn at FY2026, against revenue of ZAR 0.9 bn. 2. **Dependence on the municipal and political environment.** This affects approvals, infrastructure cost recovery, subsidy flows and security of sites (land invasions). 3. **A small but strategically important annuity-like cemetery business.** At FY2026 it generated about R107 m of cash receipts on about 10% of revenue, but with gross margins of about 55%. Accounting profits have consistently run well ahead of operating cash flow. The investment debate therefore centres on how the balance sheet converts to cash rather than on reported earnings.

Revenue$0.0B
Employees143
Market CapN/A
Founded1995
United States, North America
BYON

BYON Co., Ltd.

Premium
Information Technology

BYON Co., Ltd. is a 43-year-old Korean corporate shell with a long history of business reinvention. It began as Seoul Electron, an electronics company, and later operated as Polyvision, which made PVC advertising banners, tarpaulins and flooring. From 2016 it repositioned under the BYON name as a "bio-medical" company. In practice, most of its revenue came from trading high-pressure-processed red ginseng raw materials, supported by a minority stake in stem-cell developer MiraeCell Bio. From late 2023, a change of control to CTM Co., Ltd. pushed the business into unrelated industrial assets: hydraulic machinery (CM Tech), a minority stake in Gwangjin Sanjeon, fuel sales and ship components. Repeated failed control transfers, disclosure violations, and criminal complaints against management followed. The company recorded net losses every year from FY2015 to FY2025, received a disclaimer audit opinion for FY2025, and was delisted from KOSDAQ on 1 July 2026. --- ### Company's own description (latest available investor material) The most recent investor-relations presentation found is the May 2021 IR deck [S18]. It described BYON as a KOSDAQ-listed small or medium enterprise whose main businesses were cosmetics manufacturing and sales, plus distribution of health functional food raw materials. The deck organised operations into three divisions: Bio-medical, at roughly 82% of FY2020 separate revenue; Cosmetics, at roughly 9%; and Auto parts, at roughly 1%. The deck made five main points: **Bio-medical:** The core activity was processing ginseng into red ginseng raw materials using high-pressure technology. Supply came from a farm partner in Geumsan under a December 2015 alliance with Baeknyeon F&G. The output was sold as an input for cosmetics, pharmaceuticals and health supplements. Customers included large domestic companies and pharmaceutical firms; the deck names Amorepacific and Ilyang Pharmaceutical [S18]. **Stem cells:** BYON held 23.53% of affiliate MiraeCell Bio (미래셀바이오), which was developing stem-cell therapies and preparing for a KOSDAQ technology-special listing [S18]. **Medical devices:** BYON planned to build a GMP facility for contract manufacturing of stem-cell-applied wound dressings and in-vitro diagnostic devices. For this it acquired roughly 940 m² in the Gwangmyeong medical cluster [S18]. **Financial profile:** Management stressed a "no-borrowing" stance: a debt ratio of 19.13% and current ratio of 347.90% at FY2020 (consolidated) [S18]. Third-party profiles based on later filings describe a broader and more fragmented business. Stockopedia reported that the company ran eight reporting segments: bio-medical, cosmetics, health supplements, fuel sales, ship components, hydraulic motors, automotive parts, and others [S25]. Simply Wall St and Morningstar describe stem-cell cell-therapy development and cardiomyocyte commercialisation, supply of health functional food ingredients, and cosmetics, cosmetic containers and auxiliary materials [S13a][S26]. ### Independent characterisation Based on the filing trail, BYON is best understood as a listed holding vehicle whose operating mix followed whoever controlled it, not as a focused operating company: **1983–2015 (Seoul Electron / Polyvision era):** industrial products. These included advertising banners ("banner flex"), tarpaulins and PVC flooring, made at a plant in Ochang, Chungcheongbuk-do [S23][S24]. - **2016–2023 (BYON "bio" era, under the Kim Byung-joon management):** a trading-led red-ginseng raw-material business. Smaller contributions came from cosmetics (including the STEMELIN brand launched in 2022), auto-parts trading, and furniture or beauty-device trading. The bio narrative depended on equity stakes in MiraeCell Bio and other affiliates rather than on in-house R&D. Disclosed R&D spend never exceeded ₩1.3 billion a year. **2024–2026 (CTM era, under CEO Ryu Jin-hyung):** the company bought industrial assets connected to its new controlling shareholder. It took 28% of Gwangjin Sanjeon in March 2024 [S10] and 100% of CM Tech, a heavy-equipment parts and hydraulic machinery maker, in May 2024 [S17]. By 2025, Pharmatimes reported that most revenue came from fuel and ship-parts sales, while bio-medical revenue had fallen from ₩9.6 billion in 2021 to ₩0.2 billion in 2024 [S6]. ### Business model and revenue model | Dimension | Assessment | |---|---| | Product vs. service vs. subscription vs. licensing | Almost entirely product sales and merchandise trading. The 2018–2021 segment tables classify bio-medical, cosmetics and auto-parts revenue as merchandise (상품) sales, not manufactured goods [S18]. No subscription or licensing revenue is disclosed. | | Value-chain position | Mid-stream processor and trader of red ginseng raw materials (2016–2023), then a downstream holder of industrial operating subsidiaries (2024–2026) | | Customer types | B2B: large consumer-goods and cosmetics firms, pharmaceutical companies, food companies, shipyards and industrial buyers. Limited B2C through the STEMELIN cosmetics brand via home shopping [S27]. | | End-markets | Korean health functional foods, cosmetics, automotive parts, hydraulic machinery and heavy equipment parts, marine and ship components, fuel distribution | | Revenue concentration | High. In FY2020, one product category (red ginseng raw materials) made up 81.76% of separate revenue [S18]. |

Revenue$0.0B
Employees17
Market CapN/A
Founded1983
United States, North America
BYC

BYC Co., Ltd.

Premium
Information Technology

BYC is Korea's oldest branded innerwear maker. It was founded in 1946 and built its name on basic cotton "meriyasu" undershirts, briefs and long underwear. It has since repositioned toward functional seasonal lines: BODY HEAT, a heat-generating thermal range, and BODY DRY, a cooling range. Underneath the consumer brand, BYC has become a property company in economic terms. It holds 34 commercial buildings, four officetels and a knowledge-industry centre across 39 Korean commercial districts. Investment property was carried at KRW 449bn at end-2024 against a disclosed fair value of about KRW 1.19tn. The leasing and construction segment produced roughly three-quarters of 2024 operating profit on under 30% of revenue. The company is now committing KRW 394bn, about 70% of book equity, to redevelop its former Seoul headquarters site into the 40-storey "GD Metro Tower". The equity case rests on deep asset discount, family control of 72.66%, and an evolving Korean governance regime. --- **What the company does.** BYC runs three reportable businesses. 1. **Textiles (섬유).** Design, manufacturing, sourcing and wholesale/retail of men's, women's and children's innerwear, thermal wear, cooling wear, lingerie, sleepwear, socks, hosiery and, since 2022, pet apparel. 2. **Construction sales and leasing (건설분양·임대).** Leasing of an owned national portfolio of commercial buildings, officetels and a knowledge-industry centre. This segment also covers construction contracting and sales, now centred on the GD Metro Tower officetel/office development. 3. **Advertising agency (광고대행).** Immaterial in size. It generated a KRW 0.1bn operating loss in 9M 2025. Sources: Yahoo Finance profile; Huffington Post Korea (7 Dec 2025); Stockhub. **Company's own description.** The company describes itself as Korea's representative innerwear specialist, centred on innerwear manufacturing and wholesale. It also lists contract construction, construction sales, rental services and advertising agency services as business lines (Catch.co.kr company summary; Yahoo Finance profile). The latest annual report narrative was not directly reviewed. Its verbatim self-description is therefore not reproduced beyond this paraphrase. **Business and revenue model.** **Product revenue (textiles):** about 70–75% of revenue. Sales run through a mixed channel model: official online mall, directly operated stores (including outlet-style stores next to HQ and at BYC Hi-City in Gasan-dong), franchised stores, marts and live commerce. One data vendor reports about 1,700 franchise outlets and 14 company-owned chain stores. This count is undated and should be treated as possibly outdated (Stoxray; Wisesheets). **Rental revenue (leasing):** about 25–30% of revenue at around 37–41% segment operating margin (derived, Section 4). This is recurring, contract-based income. **Development/sales revenue (construction sales):** currently minor. It will become lumpy and material as GD Metro Tower officetel units are sold from October 2026 and recognised over construction or at completion (accounting method not disclosed). - No subscription or licensing revenue is disclosed. **Value-chain position.** Historically BYC was vertically integrated "from yarn to finished garment", with knitting and garment plants in Iksan, Jeonju, Seoul (Guro) and China (Plunkett; Jeonbuk Ilbo 2002 interview). The domestic plants have since closed or been redeveloped. A 2024 government notice describes BYC's order flow as goods *produced in overseas factories, imported, then repackaged and distributed* through its automated Wanju logistics centre (MOLIT via Taxtimes/Hellot, 28 May 2024). BYC is therefore now mainly a brand owner, designer, sourcer and distributor, with an Indonesian subsidiary (PT. BYC Indonesia, 98.96% owned) in the supply base (etfshopping/DART). **Customer types and end-markets.** **Textiles:** Korean mass-market consumers, skewed to middle-aged and older shoppers and family/gift purchases (e.g., Lunar New Year BODY HEAT gifting promotions). Younger consumers are targeted through cooling outerwear-style lines and online/live commerce. Exports were only 1.7% of FY2025 revenue (KRW 2.85bn) (Valueline TTM data). **Leasing:** commercial tenants in 39 key Korean commercial districts (Trustone open letter, March 2023, via Huffington Post Korea). **Development:** residential-use officetel buyers and office occupiers near Guro Digital Complex station (G-Valley: ~100,000 firms, ~500,000 workers) (Newsway via Daum, Sep 2026). **Independent characterisation.** BYC is best analysed as a low-growth, cash-generative consumer brand attached to an under-earning, under-levered real-estate holding company. Textiles revenue fell from KRW 127.4bn (2022) to KRW 116.6bn (2024), and segment operating profit is thin (KRW 5.9bn in 2024). Group earnings stability depends on rent. The strategic centre of gravity has shifted to property monetisation: the GD Metro Tower development, the listing of Jeonbuk industrial land for sale, and earlier the Gasan "BYC Hi-City" redevelopment. Capital allocation and governance, not apparel demand, are the main value drivers.

Revenue$0.1B
Employees544
Market CapN/A
Founded1946
United States, North America
Burgenland

Burgenland Holding Aktiengesellschaft

Premium
Information Technology

Burgenland Holding AG is a listed, debt-free, staff-less holding company. Its sole economic purpose is to own 49% of Burgenland Energie AG, the regional utility of Austria's easternmost province. The remaining 51% of Burgenland Energie is controlled by the provincial government through Landesholding Burgenland GmbH. BUHO also owns a 0.99% stake in Wiener Börse AG. The company has no revenue, no capital expenditure and no operating business. Its earnings consist almost entirely of the annual dividend Burgenland Energie pays, plus small interest income on cash deposited with its parent, EVN AG. BUHO distributes essentially all of its net income: EUR 4.05 per share for FY2024/25, a payout of about 100%. With a free float below 10% and an average of about 20–30 shares traded per day, the stock is effectively a closely held, low-volatility income instrument. Its value depends on Burgenland Energie's ambitious, capex-heavy programme to make Burgenland energy-independent by 2030. --- ### Company's own description (paraphrased from the FY2024/25 Annual Financial Report) The company describes its business as holding and administering participations. It holds 49% of the share capital of Burgenland Energie AG, whose share capital is EUR 34.9m. The other 51% belongs to Landesholding Burgenland GmbH. BUHO also holds shares in Wiener Börse AG. The company states that it records no revenue (Umsatzerlöse). Its result is mainly determined by the dividend of Burgenland Energie AG, and it employs no personnel [S1]. ### Independent characterisation BUHO is a pass-through dividend vehicle created during the privatisation of the Burgenland utilities. The investment case has three layers: **Layer 1 – BUHO itself:** The balance sheet is EUR 82.6m, almost entirely book-value equity stakes (EUR 71.3m) and cash deposited at EVN (EUR 11.2m). There is no debt. Annual overhead is roughly EUR 0.28m, covering the EVN service fee, listing costs, board fees and publications [S1]. **Layer 2 – Burgenland Energie Group:** This is a vertically integrated regional utility with wind and PV generation, electricity and gas distribution grids, retail supply of electricity, gas and heat, district heating, e-mobility and energy services. Revenue was EUR 704.7m in FY2024/25 (prelim). The group is Austria's largest wind power producer by its own and BUHO's description [S1]. **Layer 3 – Control architecture:** EVN, controlled by the Province of Lower Austria, controls BUHO. The Province of Burgenland controls Burgenland Energie through Landesholding. A syndicate agreement between BUHO and Landesholding governs Burgenland Energie and gives each party a call right on the other's BE shares if control changes at either shareholder [S1]. In practice, BUHO's minority shareholders hold an indirect, non-controlling interest in a province-controlled utility. ### Revenue model mix | Income source (BUHO) | Nature | Share of FY2025 income sources (%) | |---|---|---| | Dividend from Burgenland Energie AG | Equity participation income (49% stake) | 94.5 | | Dividend from Wiener Börse AG | Equity participation income (0.99% stake) | 2.8 | | Interest on short-term deposits with EVN AG | Treasury income | 2.7 | | Product / service / subscription / licensing revenue | None | 0.0 | The percentages are analyst calculations from FY2024/25 P&L line items [S1]. ### Value chain position and end-markets (look-through via Burgenland Energie) | Value-chain stage | BE activity | Key evidence | |---|---|---| | Generation | Wind (197 turbines, 564 MW attributable, about 1,088 GWh in FY2024/25), utility-scale and rooftop PV, biomass heat, battery and salt storage | [S1] | | Networks | Electricity and gas distribution through Netz Burgenland GmbH (100%). Electricity network delivery 1,651 GWh and gas network delivery 1,851 GWh in FY2024/25 | [S1] | | Retail / supply | BE Vertrieb GmbH & Co KG: 957 GWh electricity and 751 GWh gas sold to end customers in FY2024/25 | [S1] | | Heat | Energie Burgenland Fernwärme GmbH, with heating plants in Eisenstadt (14 MW biomass) and Bad Tatzmannsdorf (10 MW wood chips) | [S1] | | Trading / services | BE Trading GmbH (new by FY2025), BE Solution, BE Service, BE Technology, BE Finance, energy communities | [S1] | **Customer types (BE):** households, municipalities (for example the "Gemeindepaket Energiesicherheit" since April 2025), commercial and agricultural businesses, industrial offtakers (Borealis PPA of about 70 GWh/year from January 2026), and energy-community members [S1][S3]. **End-markets:** the Austrian regulated distribution market in Burgenland, the Austrian and Central European wholesale power market for merchant renewable output, the Austrian retail electricity and gas market, and the regional district heating market.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1990
Eisenstadt, Austria
Bukwang

Bukwang Pharmaceutical Co., Ltd.

Premium
Information Technology

Bukwang is a 66-year-old, mid-sized Korean prescription-drug company. In 2022 it moved from founder-family control to the OCI Group, and the business now runs on three engines. The first is a domestic ETC franchise led by diabetic-neuropathy products (Dexid and Thioctacid), liver therapy (Legalon) and iron supplementation (Feroba). The second is a fast-growing CNS franchise built around in-licensed lurasidone (Latuda, launched August 2024), with Exel, Zaledeep, Orfil and the 2026 epilepsy launch Bukwang Brivil alongside it. The third is a Copenhagen-based discovery subsidiary, Contera Pharma, which combines a Phase 2-ready Parkinson's asset (CP-012) with an oligonucleotide/RNA discovery platform validated by an October 2025 research option deal with H. Lundbeck. After two loss years (FY2022–23) and a deep restructuring, Bukwang posted record revenue of KRW 200.7bn in FY2025 and raised KRW 89.3bn of equity. It then bought a court-rehabilitated manufacturer to relieve chronic capacity shortfalls. Management targets KRW 600bn revenue and a top-20 domestic ranking by 2030. --- ### What the company does Bukwang develops, manufactures, in-licenses and sells finished pharmaceuticals in Korea. Dosage forms include oral solids, injectables, oral solutions, topical solutions and ointments, plus quasi-drugs such as toothpaste [company/aggregator descriptions; IR FY2025]. The company describes its business as making and selling medicines and quasi-drugs. Its stated management philosophy is to contribute to a stable supply of medicines and serve society through high-quality production, with an ambition to become a global pharma-bio company [IR FY2025 Fact Book, "Vision"]. Bukwang calls its R&D model "Global Open Innovation". In practice that means subsidiaries, joint ventures, research collaborations, equity investments and fund commitments, focused on CNS and oncology [IR FY2025]. ### Business model and revenue model **Product sales dominate:** Revenue is almost entirely product sales to wholesalers, hospitals and pharmacies in Korea. Manufactured products ("제품") sit alongside traded and co-promoted goods ("상품"). An aggregator breakdown of Q2 FY2026 revenue shows other manufactured products 31%, merchandise (traded goods) 22%, Dexid 9%, Feroba 7% and Latuda 7% [butler.works, sourced from DART, Q2-2026]. **Licensing and collaboration revenue is emerging:** Contera Pharma booked about KRW 10.7bn in FY2025, believed to be largely the Lundbeck upfront payment [Dealsite, Jun-2026]. Further Lundbeck research funding was recognised in Q2 FY2026 [Dailypharm, Jul-2026]. Future milestones and royalties are possible. **Contract manufacturing (CMO) is nascent:** Bukwang Unipharm (formerly Korea Union Pharm) began contract-making Bukwang products in June 2026. Management has said a synthetic-drug CDMO business is a medium-term option once capacity stabilises [Dealsite, Jun-2026; Medigatenews, Jul-2026]. **Co-promotion:** Since 1 April 2026 Bukwang co-promotes Servier Korea's Acertil and Vastinan brands (7 SKUs), covering hospitals and clinics under 300 beds [Dailypharm, Mar-2026]. **Exports are immaterial:** An aggregator shows FY2025 export revenue of KRW 0.7 x 100M [valueline.co.kr]. Overseas revenue in practice comes from Contera's collaboration income. **No subscription model:** ### Value-chain position Bukwang is an integrated, domestic-market finished-dose company. It covers formulation R&D and in-house incrementally modified drugs (IMDs, "개량신약"), in-licensing of foreign originals, manufacturing at Ansan (and Wonju from 2026), and specialty sales forces. It does not produce APIs at scale; raw-material supply problems hit certain antivirals in 2023 [IR FY2023]. Since 2023 the Ansan plant has run above 100% utilisation (115% in Q1-2026; 122% average in late 2025). About 20% of FY2025 revenue relied on outsourced production [Dailypharm, May-2026; Dealsite, Jun-2026]. ### Customers and end-markets **Customers:** pharmaceutical wholesalers, tertiary and general hospitals, psychiatric hospitals, clinics, pharmacies (OTC and toothpaste) and, through Contera, global pharma partners (Lundbeck). **Therapeutic end-markets:** diabetic neuropathy and complications; CNS (schizophrenia, bipolar depression, depression, insomnia, epilepsy, dementia); hepatology (Legalon, Regadex, legacy hepatitis-B antivirals); haematology/nutrition (Feroba); gastroenterology (Selbex, pancreatin combination); cardiovascular and metabolic (Servier co-promotion, Eroset, Budiang); consumer health (Tacenol, Sirinmed toothpaste). ### Independent characterisation Bukwang is a turnaround and re-rating story inside a chemical conglomerate's pharma ambitions. The ETC base is steady and low-growth; the 2025 jump came mainly from recovered supply of the thioctic-acid franchise and the Latuda launch. Underneath sit a capacity bottleneck now being fixed through acquisition, and an option-like R&D subsidiary. Contera has consumed about KRW 120bn of Bukwang capital over 12 years [Dealsite, Jun-2026] and only in 2025 produced external validation. Group-level questions also bear on the equity story: OCI Holdings' need to reach 30% ownership by September 2027 and its own solar-sector exposure.

RevenueN/A
Employees611
Market CapN/A
Founded1960
United States, North America
Buka

Buka Investments Limited

Premium
Information Technology

Buka Investments Limited is a dormant former listed shell. For about fifteen years it was the listed parent of a South African beauty and wellness franchisor whose brands were Placecol Skin Care Clinics, Dream Nails Beauty Salons and Perfect 10 Nail and Body Studios. It also owned the Placecol skin care product range. The operating group lost revenue for years, falling from R101.1m in FY2016 to R19.0m by FY2022. COVID-19 then forced a restructuring. An Absa Bank COVID-19 loan required the operating subsidiary to sit outside a JSE-listed group, so management sold every subsidiary to the related-party i-BLOOM group for R7.63m. A new controlling shareholder, B&B Media, took 61.26% of the empty listed vehicle. B&B Media renamed the company Buka Investments and planned a reverse takeover into fashion footwear (Socrati Footwear and Caralli Leather Works). That deal was shelved in February 2023. The JSE suspended the shell and later removed its listing on 4 September 2024. Today Buka is an unlisted company with negligible net assets and no disclosed operations. --- ### The company's own description (paraphrased from its latest operating-era filings) In its FY2020 results (year ended 29 February 2020), Imbalie Beauty described itself as a beauty and wellness solutions group. It said its primary focus was developing, growing and innovating its own skin care product brands and treatments, delivered through a franchise salon footprint of three chains: Placecol Skin Care Clinics, Perfect 10 and Dream Nails Beauty Salons. It said its skin care brands reached consumers through its own salon footprint, large retail groups, pharmacies, independent salons and online platforms. (Source: Imbalie Beauty reviewed provisional results FY2020, 7 Aug 2020.) After the disposal, Buka's FY2023 audited results (31 May 2023) describe the company as a listed shell on the JSE. They say it intended to acquire "earmarked fashion businesses", subject to board, shareholder and JSE approval. Profile ShareData's company summary describes Buka's intended model as a house of brands: retailers of exclusive shoes and accessories sourced internationally and locally, with the Socrati and Caralli acquisitions pending. Those acquisitions never completed. ### Independent characterisation **Phase 1: operating beauty franchisor (2007 – January 2022).** The business model was a hybrid of three things: 1. A franchisor, earning royalties and fees from franchised salons. The group had more than 150 salons nationally in FY2016 and January 2018. 2. A brand owner and distributor of its own skin care brands (Placecol, Skinderm) and of third-party professional brands. Products were sold into the salon network, retailers (including in-store beauty outlets in Edcon stores) and pharmacies. 3. A training provider through the Imbalie Beauty Training Academy, later the Imbalie Beauty Wellness Academy and the i-BLOOM Beauty & Wellness Academy. The group also owned corporate salons until FY2017, when it decided to close them. Until 2020 it held head leases on behalf of franchisees, which created contingent liabilities. **Phase 2: cash shell (February 2022 – September 2024).** From February 2022 the listed company held only cash, receivables and a deferred tax asset. It had no revenue. Its expenses were mainly JSE, sponsor, audit, legal and directors' fees. **Phase 3: unlisted dormant entity (September 2024 – present).** No public information was found on its activities, assets or any later transaction. ### Revenue model mix (operating era) | Revenue stream | Description | Disclosed split | |---|---|---| | Product sales (own brands) | Placecol and Skinderm skin care sold to salons, retailers and pharmacies | Not publicly disclosed | | Product sales (third-party brands) | Imported international professional brands | Not publicly disclosed. Management said it deliberately shifted toward own brands in FY2020–FY2022 to lift gross margin | | Franchise royalties and fees | Royalties from franchised salons | Not publicly disclosed. Royalties received from the related-party Beauty Flagship salons were R1.197m (FY2019), R540k (FY2020) and R1.21m (FY2022) | | Training | Academy courses (34 courses offered in FY2017) | Not publicly disclosed | | Rental income | Property (Imbalie Innovation) let to related parties such as Amka Products | R90k (FY2020), R152k (FY2021), R114k (FY2022) to Amka Products | The group never reported by segment. It stated that it was managed as one operating unit (IFRS 8 disclosure, FY2020–FY2023). ### Value chain position, customers and end-markets **Value chain:** A brand owner and franchisor in the middle of the professional beauty value chain. Manufacturing appears to have been outsourced (the FY2020 results reference brand development but no factories). Distribution was outsourced in FY2017 (BusinessDay, 2 Jun 2017). **Customer types:** Franchisees, independent salons, large retail groups such as Edcon, pharmacy groups (a pharmacy group ordered Placecol for 93 new outlets on 26 March 2020), and end consumers through online channels and the Customer Solutions Division launched 3 August 2020. **End-markets:** Professional salon treatments and retail skin care in South Africa, with some cross-border sales in Southern Africa (BusinessDay, 31 Jan 2018; FY2020 IFRS 8 note).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2020
Parktown, South Africa
BuffaloCoal

Buffalo Coal Corp.

Premium
Information Technology

Buffalo Coal is a small, single-region underground coal producer in the Klip River coalfield near Dundee, KwaZulu-Natal. Through BC Dundee and its 70%-owned Zinoju Coal (Pty) Ltd it holds two mines. Aviemore East produces anthracite, mainly for domestic metallurgical and reductant users, and was approaching depletion in 2023. Magdalena produces bituminous thermal coal; its underground mining stopped in October 2018 and was restarted in phases from 2022. The company also holds two anthracite growth projects, Balgray and Aviemore North Adit, plus the Coalfields wash plant, a calcine plant and a rail siding. For most of 2015 to 2022 it was effectively controlled by Resource Capital Fund V and financed by a US$27 M convertible loan that it could not repay, and it carried a shareholders' deficiency of about R0.4 billion. In 2022 Belvedere Resources DMCC, a Dubai-based coal investor affiliated with Ikwezi Mining, bought RCF's position for about US$2.5 M, recapitalised the business and took it private. It now operates as a captive asset in Belvedere's KwaZulu-Natal coal portfolio. --- **Company's own description (paraphrased from FY2021 AFS, Note 1, and 2022 press releases).** Buffalo Coal describes itself as a coal mining and supply company operating in South Africa. It owns 100% of BC Dundee, which has an interest in two coal mines and two coal projects in KwaZulu-Natal. BC Dundee holds 70% of Zinoju Coal (Pty) Ltd, which holds all mineral rights. The remaining 30% of Zinoju is held by Black Economic Empowerment (BEE) partners, as required under South Africa's mining charter framework. The group extracts, washes and sells coal. **Business model.** The model is a vertically integrated mine, wash and sell operation: **Mining:** underground room-and-pillar mining. At Aviemore the company mined itself. At Magdalena, mining was outsourced to STA Coal Mining Company (Pty) Ltd until October 2018 (2019 AFS; Modern Mining). **Beneficiation:** run-of-mine (ROM) coal from Aviemore East is trucked about 14 km to the Coalfields washing facility in Dundee. Magdalena feeds its own on-site washing plant. A calcine plant at Coalfields produces calcined anthracite. **Logistics:** product moves by road and rail. The Coalfields rail siding links to the export port at Richards Bay. In 2011 Forbes Coal disclosed export capacity through the Richards Bay Coal Terminal (RBCT) allocation and Grindrod's Navitrade terminal. **Sales:** product is sold to domestic industrial and metallurgical customers and to export buyers. Export thermal coal is priced off the API4 (Richards Bay) index in US$ (FY2019 and FY2021 AFS, Note 3.2). Toll-washing services for third parties are a minor revenue line. **Revenue model mix.** Revenue is close to 100% product sales recognised at a point in time, with no subscription or licensing component. Toll washing was R6.6 M (2.1% of revenue) in FY2020 and R0.2 M in FY2021 (FY2021 AFS, Note 5). From 2022 the company also earned revenue from coal traded or sold to Belvedere-group affiliates: R74.9 M of Q3 2022 sales went to Belvedere and R6.1 M to Ikwezi Mining FZE (Q3 2022 interim, Note 16). It also bought ROM coal from Ikwezi Mining (Pty) Ltd and accrued a R35.0 M provision for the transport of traded coal to port, which indicates a new coal-trading activity. **Value chain position.** Buffalo is an upstream primary producer with captive beneficiation. It has no downstream conversion apart from calcining, and it depends on third-party rail (Transnet) and port infrastructure. **Customer types and end-markets.** **Independent characterisation.** Buffalo Coal was a sub-scale, high-cost, balance-sheet-impaired producer whose public-market existence from about 2015 was largely a creditor-controlled holding structure. A single private-equity lender (RCF) held both the controlling equity and a convertible loan that exceeded total assets by more than two times. Its operating economics depended on one shrinking anthracite adit (Aviemore East). Its strategy in 2019 to 2022 was to bridge to Balgray, a roughly seven-year anthracite extension, while re-opening Magdalena to diversify away from anthracite. Belvedere's 2022 entry changed the investment case. A strategic owner with trading, logistics and a nearby KwaZulu-Natal mining affiliate (Ikwezi) replaced a financial owner that was seeking to exit. Belvedere refinanced the RCF debt it had bought at a deep discount through an intra-group US$30 M facility and removed the listing.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
Dundee, South Africa
Budapesti

Budapesti Ingatlan Hasznositasi es Fejlesztesi Nyrt.

Premium
Information Technology

BIF is a small-cap Hungarian REIT, controlled by a single family, that owns a Budapest-only portfolio worth about HUF 88.9 billion (fair value at 30 June 2026). The portfolio comprises ten office buildings (four Category A, six Category B), two parking garages, two hotel-use buildings, a boutique rental residential building in the Castle District, a heritage development site on Andrássy út, and the remainder of a 39-hectare residential land bank at Harsánylejtő in District III. One development plot in Volosko, Croatia, is carried at cost. The model is overwhelmingly rental income, supplemented by episodic land sales and, since 2025, by a fast-growing general-contracting line run by a subsidiary. The balance sheet is conservative. Net debt was about HUF 3.6 billion at June 2026, all debt is long-term, fixed-rate and in HUF, and equity accounts for roughly 78% of assets. BIF's distinguishing features are low leverage, REIT tax exemption, high reported returns that are inflated by revaluation gains, and concentrated ownership with significant political-economy exposure. That exposure comes from the controlling family's public profile and from the presence of state-linked tenants. --- ### Company's own description (FY2025 Board Report / H1 2026 Report, paraphrased) BIF says it develops and utilises its own properties: offices and other buildings, plus parking garages. It earns income by leasing them, developing them further, selling construction plots it owns, carrying out developments on those plots, and leasing or selling the completed properties. It defines its activity across five property-market segments: office buildings, parking garages, building plots, residential properties, and hotels. For hotels, BIF stresses that it earns no accommodation or catering income itself; it only leases the buildings to operators. The stated strategic pillars (unchanged from 2022 to 2026) are: 1. identifying and acquiring office and other buildings that fit the existing income-generating portfolio; 2. maximising the income potential of the existing portfolio and optimising the operation of office buildings; 3. implementing the fully developed concept for the 39-hectare Harsánylejtő development site (District III, Budapest). ### Business model and revenue model | Revenue stream (H1 2026) | HUF '000 | Share of net sales (%) | Character | |---|---|---|---| | Rental and operating fee revenue | 4,626,540 | 55.5 | Recurring; indexed leases | | Parking fee revenue | 406,342 | 4.9 | Recurring; passes and hourly | | Revenue from mediated (recharged) services | 672,050 | 8.1 | Pass-through of tenant fit-out, utilities and service charges | | Revenue from property/land sales | 132,671 | 1.6 | Episodic (7 Harsánylejtő plots) | | Revenue from building construction projects | 2,076,798 | 24.9 | Subsidiary general contracting on plots already sold to third parties | | Other revenues | 416,604 | 5.0 | Includes restaurant revenue (Marischka) and miscellaneous | | Total | 8,331,005 | 100.0 | — | BIF is a landlord/REIT with a residual development and trading arm. Its revenue model, using the H1 2026 net sales breakdown (HUF thousand), is shown below. Source: BIF 2026 Half-Year Report, Note 21. Percentages are analyst calculations. Using the categories requested, the mix in H1 2026 was: **Service/lease income:** (rental + parking + mediated services): about 68%. The company itself states that 68% of consolidated net sales came from rental, parking, operating-fee and service revenues. **Project/contracting income:** about 25%. **Asset sales:** about 2%. **Hospitality/other:** about 5%. BIF has no product, subscription or licensing revenue. ### Value-chain position BIF is vertically integrated across the property cycle, from acquisition to ownership to management. In-house teams handle property management, operations, maintenance and leasing. In-house engineering supports developments. The subsidiary Harsánylejtő Kft. now acts as general contractor and adviser on third-party developments on plots it previously sold. A further subsidiary, Marischka Kft., runs food and beverage outlets inside BIF buildings: the Marischka restaurant at Attila99Loft, Babutzi Breakfast/Brunch at Major Udvar, and the restaurant at Flórián Udvar. These outlets act as an amenity layer for tenants. ### Customer types and end-markets **Office tenants:** corporates and public-sector or state-owned entities. Examples documented in the press: - the Ministry of Agriculture moved into the Vigadó Palota Office Building from late 2018 (HVG/Economx, 2018); - MÁV (Hungarian State Railways) leased the Kassák-Dévai office building via a BIF subsidiary until end-2026 (Telex, June 2024); - Magyar Posta is a tenant at Városmajor 35 (Privátbankár, 2020). - BIF Tower is leased to a single tenant as its standalone headquarters. The tenant's identity is not publicly disclosed in BIF filings. **Parking customers:** season-pass holders, hourly users, event users, and EV-charging users at the Aranykéz garage. **Hotel operators:** lessees of the Madách tér building (being refurbished; re-letting in negotiation) and of the "BIF Hostel" building (lease terminated March 2026). **Residential tenants:** the 16 flats plus commercial units at Attila99Loft. **Land buyers and developers:** buyers of Harsánylejtő plots, who in some cases then hire Harsánylejtő Kft. as general contractor. ### Independent characterisation BIF is best understood as a Budapest office REIT with optionality. Roughly 69% of H1 2026 net sales and essentially all of segment profit come from the income-generating property segment. The remaining activities are sizeable relative to BIF but small in absolute terms: land, contracting, hospitality and heritage redevelopment (Madách tér, Andrássy út 80-82). Three features distinguish BIF from a typical European REIT: 1. **Very low leverage.** Net debt was about 4% of the investment property value at 30 June 2026 (analyst calculation). 2. **Volatile reported profits.** Fair-value changes run through operating income, so headline EBITDA and net margins often exceed 100% of revenue. 3. **Material governance and political-economy overlay.** The controlling family (Mária Schmidt and her children Dr Anna Ungár and Péter Ungár) is prominent in Hungarian public life, and part of the tenant base is state-linked. This has drawn persistent press scrutiny and is a principal risk after the April 2026 change of government.

RevenueN/A
Employees69
Market CapN/A
Founded1994
United States, North America
Bucket

Bucket Studio Co., Ltd.

Premium
Information Technology

**Positioning statement (analyst, about 150 words).** Bucket Studio is a micro-revenue Korean media-and-services holding company. Its listed value has become detached from its operations. The operating business generated KRW 17.3bn of FY2025 revenue across four activities: bulk SMS/LMS marketing messaging under the 문자천국 / 9원문자 / 문자조아 / 문자팝 brands; film and drama ancillary-rights distribution; a five-screen Megabox franchise theatre in Sejong; and kiosk leasing plus F&B run through its 78.89% subsidiary Inbiogen. The business has lost money at the operating level for five consecutive years. The equity story is about governance, not operations. Bucket sits at the top of a circular chain (Initial No.1 → Bucket → Inbiogen → Vident → Bithumb Holdings) that gives it an indirect economic interest in Bithumb, Korea's second-largest crypto exchange. Since the 2023 embezzlement and breach-of-trust case against the controlling family, the company has been suspended. Its survival as a listed company now depends on closing the KRW 100.1bn NMSI change-of-control transaction before the KRX improvement period ends. --- ### Company's own description (latest filing, paraphrased) In its H1 2026 half-year report, the company describes itself as follows [S1]: - It supplies film, video and educational content to smart-device platforms (IPTV, cable, smart TV, tablets). - It runs mobile services centred on bulk text messaging. - Its principal subsidiary runs kiosk distribution and food-and-beverage (F&B) operations. The filing describes the messaging business as largely insensitive to the economic cycle: - In downturns, businesses use SMS as the cheapest marketing channel. - In upturns, small merchants and local self-employed businesses use it as a core marketing tool. The content arm acquires ancillary rights to domestic and foreign films through direct and indirect investment. It monetises them across online download, IPTV, terrestrial and cable TV, satellite and mobile. ### Business model and revenue model | Revenue type (company classification) | Model | H1 2026 revenue (KRW m) | Share | Source | |---|---|---|---|---| | Service revenue — bulk messaging (Digital Biz) | Prepaid coupons or direct purchase through company-run websites; per-message pricing of KRW 9–300; recognised over time | 6,193 | 63.8% | [S1] | | Kiosk lease revenue (Inbiogen) | Finance leases of kiosks to restaurants, coin karaoke and franchise outlets; monthly CMS collection plus payment-commission income | 2,197 | 22.6% | [S1] | | Content revenue — ancillary rights | Licensing of acquired content to cable, lodging and DVD rooms (period sales) and to OSP/VOD/IPTV (per-transaction, settled monthly) | 345 | 3.6% | [S1] | | Online revenue — download | Content supplied to P2P/webhard operators under OSP contracts | 320 | 3.3% | [S1] | | Theatre ticketing | Megabox Sejong franchise, 5 screens | 368 | 3.8% | [S1] | | Theatre concessions | Snacks and beverages | 160 | 1.6% | [S1] | | F&B (Inbiogen) | Restaurant/bar under the "Forest" (포레스트) brand; immediate cash settlement | 99 | 1.0% | [S1] | | Other (rent / services) | Minor | 22 | 0.2% | [S1] | | Total | — | 9,704 | 100% | [S1] | **Mix characterisation (analyst):** - About 64% of H1 2026 revenue is transactional, usage-based service revenue from messaging. - About 23% is lease or annuity-like income from kiosks. - About 12% is content licensing and theatre. - There is no subscription or meaningful licensing-IP revenue. - The company has no production facilities and no raw materials [S1]. ### Value-chain position and customers **Messaging:** Bucket is a reseller and aggregator, not a carrier. It sits between mobile network operators and SME, self-employed and enterprise senders, reaching customers through its own web storefronts. In August 2025 its articles were amended to add "special-type value-added telecom", "text-sending service" and "text resale" purposes, which formalises its reseller position [S1]. **Content:** a downstream ancillary-rights distributor. It is not a studio, despite the "Studio" name. It sells through about 30 OSPs, about 15 general VOD sites, the three IPTV operators, digital and satellite cable, and lodging and DVD-room channels [S1][S2]. **Kiosk:** distribution and leasing through Inbiogen. The FY2023 filing cited about 50 restaurant, karaoke and PC-café franchise outlets and about 30 sales-agency partners. Enjoysoft (엔조이소프트) is named as a principal customer [S1][S2]. **End markets:** almost entirely domestic Korea. Exports, limited to online download, were KRW 75m in FY2025 [S1]. ### Independent characterisation (analyst) Operationally, Bucket is a sub-scale SME services company that has shrunk from earlier ambitions. Between 2021 and 2022 it added more than 100 business purposes covering crypto exchange, blockchain, metaverse, virtual humans, AI, e-commerce, payments and education. In 2023 it deleted almost all of them, stating that the trading suspension made capital raising impossible [S1]. Its balance sheet is dominated by an equity-accounted stake in Vident (carrying value KRW 135.4bn at 30 June 2026), which is about 84% of consolidated total assets of KRW 160.4bn [S1]. The investment case therefore rests on three things: - the value and recoverability of the Vident/Bithumb look-through holding; - the KRX listing-eligibility outcome; - the legal resolution of the controlling family's criminal case. The operating businesses themselves matter much less.

Revenue$0.0B
Employees24
Market CapN/A
Founded1999
United States, North America
Bubang

Bubang Co., Ltd.

Premium
Information Technology

Bubang Co., Ltd. is the listed intermediate holding company of the Bubang Group's consumer-and-distribution arm. It is best known through its wholly owned subsidiary Cuchen (쿠첸), Korea's long-standing number-two electric rice-cooker brand behind Cuckoo. Since its 2015 demerger it has owned and managed four subsidiaries: **Cuchen:** rice cookers, induction and hybrid ranges, small kitchen appliances. **Bubang Retail (부방유통):** operates the E-Mart Anyang hypermarket. **Biz & Tech Consulting:** IT services. **SCK:** building management and staffing outsourcing. The holding company also earns rental and investment income. Consolidated revenue has been stuck in a KRW 310–340bn band since 2018, and operating margins have stayed below 1.5%. Bubang therefore trades as a deep-value, low-liquidity stock at about 0.3x book. In 2026 its share price fell below Korea's new KRW 1,000 "penny-stock" delisting threshold. Management responded by cancelling all 10.63% of its treasury shares, and insiders, including the founding family's eldest son, bought on market. Ultimate control sits with Techcross Holdings, which is led by second son and Vice Chairman Lee Jung-hee. --- ### What the company does | Subsidiary | Activity | Ownership | |---|---|---| | Cuchen Co., Ltd. (㈜쿠첸) | Electric rice cookers (IH pressure, IR, micom), induction and hybrid electric ranges, other kitchen appliances; brand "CUCHEN" | 100%, wholly owned since the 2019 share swap | | Bubang Retail (부방유통) | Large-format discount-store operation (E-Mart Anyang) | Subsidiary; exact % not disclosed in sources reviewed | | Biz & Tech Consulting (비즈앤테크컨설팅) | IT services and consulting; aggregators also cite network-acceleration services | Subsidiary | | SCK (에스씨케이) | Building management, facility services and staffing outsourcing | Subsidiary. Former owner Lee Dae-hee sold his 100% stake in 2020 for KRW 6.2bn (Bizwatch, 2022). | Bubang is a holding company (지주회사) formed in 2015 when the former Lihom-Cuchen split its living-appliance operations into a separate company, Cuchen. Bubang retained the holding, real-estate leasing and new-business investment functions (Catch.co.kr company summary; NewsTomato 2017). Through consolidation, Bubang's financial statements reflect four operating subsidiaries (Bizwatch, 9 Sep 2026): ### Reporting segments (latest disclosed mix) | Segment (Korean) | Content | Share of Q2 2026 revenue | |---|---|---| | Living (리빙사업) | Cuchen appliances | 47% | | Distribution (유통사업) | Bubang Retail / E-Mart Anyang | 31% | | Service (서비스사업) | SCK facility and staffing services; Biz & Tech IT services | 21% | | Investment (투자사업) | Holding company leasing and investment income | 1% | Revenue mix by segment for Q2 2026, per Butler.works from the H1 2026 report: ### Business and revenue model **Product sales (Living):** Cuchen designs, manufactures and sells appliances. It sells its own manufactured products (FY2025: KRW 92.3bn) and also resells sourced merchandise (FY2025: KRW 49.6bn). - Merchandise is rising as a share of sales: own-product sales fell 27.9% YoY while merchandise rose 25.3% (NewsSpace, Cuchen FY2025 audit). - Much merchandise is sourced from the Guangdong Midea-Cuchen joint venture. **Retail revenue (Distribution):** Store sales through the E-Mart Anyang hypermarket operation. **Service fees (Service):** Contracted building-management, staffing and IT service fees, which are recurring by nature. **Holding income (Investment):** Rental income from owned real estate, royalty/technology-usage fees charged to Cuchen, and dividends from subsidiaries (eliminated on consolidation). - Cuchen owed Bubang KRW 650m of such fees at end-2025 (NewsSpace). **Subscription or licensing revenue:** none disclosed beyond the intra-group technology fees. ### Customers and end-markets **Living:** Korean households, reached through hypermarkets, department stores, TV home shopping and online marketplaces. Cuchen is highly concentrated: - Customer "A" was 30.4% of FY2025 sales (KRW 45.6bn). - Customer "B" was 10.3% (KRW 15.4bn), down 49.3% from KRW 30.4bn in FY2024 (NewsSpace). - Customers are unnamed in the audit report. - Domestic sales were 95.4% of Cuchen's FY2025 revenue. **Distribution:** Retail shoppers in the Anyang (Gyeonggi-do) catchment. **Service:** Corporate clients for facility management and outsourcing, including group affiliates (specific clients not disclosed). ### Value-chain position Cuchen is a vertically integrated brand owner. It does R&D and design in Korea, manufactures at its Cheonan plant, sources components and finished goods from a China JV with Midea, and sells through third-party retail and e-commerce. Bubang Retail sits at the downstream retail end. The service businesses are B2B intermediaries. At group level, Bubang is the consumer-facing arm of a two-pillar group. The other pillar is Techcross (ship ballast-water treatment, water treatment and energy) under Techcross Holdings. ### Company self-description vs. independent characterisation **Company/aggregator description:** a holding company established in 2015 by spinning off its living division (Cuchen), engaged in subsidiary management, real-estate leasing and new-business investment (Catch.co.kr, citing filings). Stockopedia describes it as mainly engaged in manufacturing and selling household appliances and electronic components. **Independent characterisation:** Bubang is economically a struggling mid-sized appliance brand (Cuchen) bolted to a stable but low-margin retail store and a facility-services business. It sits inside a family group whose growth capital and strategic attention have shifted to the Techcross environmental and maritime side. - The listed entity's investment case now rests mainly on asset value (P/B ~0.3x), balance-sheet repair (net cash since FY2025) and capital-return actions forced by regulation. - It does not rest on operating growth.

Revenue$0.2B
Employees238
Market CapN/A
Founded1976
United States, North America
Brikor

Brikor Limited

Premium
Information Technology

Brikor is a small, vertically integrated South African building-materials and mining group based in Nigel, on the East Rand of Gauteng. It runs two segments. The Bricks segment manufactures clay face bricks (FBA class) and plaster/non-facing bricks (NFP and NFX classes) at Plant 1 and Plant 3, with stated capacity above 150 million bricks a year. Its customers are in housing, residential, commercial, industrial and civil construction. The Coal segment owns the Vlakfontein and Grootfontein opencast mining rights. These supply clay and coal to the brick kilns and sell thermal coal, since November 2023 under a life-of-mine contract-mining arrangement with an affiliate of the controlling shareholder. Brikor also owns 40% of logistics business Zingaro Holdings. The group earned R317.7m of revenue in FY2026, all of it in South Africa. It has been loss-making in two of the last three years, carries a growing environmental rehabilitation liability, and is being taken private by its 85.88% shareholder at 17c per share. --- ### Company's own description In its FY2026 Directors' Report and interim filings, Brikor describes itself as a diversified manufacturer and supplier of building and construction materials. Its products serve applications from low-cost housing through residential, commercial, industrial, civil engineering and infrastructure projects. It reports two segments: **Bricks:** manufacture and sale of clay bricks. **Coal:** coal mining and related operations, conducted through Ilangabi Resources (Pty) Ltd (wholly owned) and Kopanela Mining (Pty) Ltd (70% owned). It also notes a 40% associate stake in Zingaro Holdings (Pty) Ltd, a South African logistics company. (Source: AFS FY2026 Directors' Report; INT25 Overview.) The website's "Our Purpose" statement frames Brikor as building its region's future by making and supplying quality building, construction and mining materials. Its stated vision, under the acronym "ASPIRE", is to be a leading player in the mining and construction sectors. (Source: brikor.net, "Who We Are".) ### Independent characterisation Brikor is best understood as a regional, commodity-grade clay-brick manufacturer with captive raw materials, attached to a small coal-mining royalty-like stream that is now largely outsourced to a related party. **Bricks.** This is the economic engine. - It has generated all of the group's positive operating profit in every year from FY2022 to FY2025. Segment operating profit was R12.5m, R15.7m, R24.5m and R26.6m respectively. - It slipped to a R2.4m loss in FY2026 as revenue fell 10.3% and gross margin collapsed from 29.2% to 13.6%. (Source: YERes23; INT24; YERes26.) - It is a manufacturing business. Clay is quarried on Brikor's own or affiliated mining rights, extruded or moulded, dried and fired in kilns, then sold ex-works or delivered. - Delivery is increasingly done with Brikor's own transport fleet. It bought R7.1m of new brick transport vehicles in FY2026. (Source: YERes26.) **Coal.** - Before November 2023, Brikor mined and sold coal itself. Segment operating losses were R12.8m in FY2022 and R5.8m in FY2023. - Since 1 November 2023, a contract miner, Ilangabi Colliery (Pty) Ltd, mines Brikor's Vlakfontein and Grootfontein rights. Ilangabi Colliery is a subsidiary of controlling shareholder Nikkel Trading 392. - Ilangabi Colliery buys all the coal it mines. Brikor's segment gross profit is in effect capped at about R20 per tonne mined, with a contractual underpin of 150,000 tonnes per month of clean run-of-mine coal. (Source: INT24, Contract Mining update.) - As a result, coal revenue is reported gross, which inflates group revenue. The economic contribution is a thin margin plus the transfer of mining cost and operating risk to the contractor. - The underpin was never met in FY2024–FY2026 because there were no off-take contracts. Off-take agreements with Eskom's Grootvlei Power Station and a private buyer were signed in September 2025, and Eskom supply began in December 2025. (Source: INT25; YERes26.) ### Business and revenue model | Dimension | Characterisation | |---|---| | Product vs service mix | About 88% product, 12% service on FY2025 disclosure. FY2025 split: clay products R183.0m (48.1%), coal minerals R162.0m (42.5%), transport of clay products and ancillary products R35.8m (9.4%). (Source: INT25 segment note, FY2025 audited column.) | | Subscription / licensing | None | | Contract structure | Bricks are sold spot or on credit terms to merchants, contractors and developers; external debtors are partly covered by credit insurance from the Credit Guarantee Insurance Corporation. Coal is sold under the life-of-mine Contract Mining and Coal Purchase Agreement (related party). (Source: INT25 note 6; INT24.) | | Value-chain position | Upstream raw-material extraction (clay and coal from own mining rights) → mid-stream manufacturing (firing bricks) → downstream distribution (own trucks; 40% of logistics associate Zingaro) | | Customer types | Builders' merchants, contractors, developers, DIY / additions-and-alterations buyers, public-sector and low-cost housing projects (bricks). A related-party contract miner, with Eskom and a private industrial buyer as end off-takers (coal). | | Customer concentration | FY2023: two customers made up 18% of group revenue (both Bricks). H1 FY2025: three customers made up 36.8% of Bricks revenue. H1 FY2026: 39% of group revenue came from one related party (Ilangabi Colliery). FY2025 related-party coal sales: R168.6m. (Sources: YERes23; INT24; INT25.) | | End-markets | South African residential construction (new builds and alterations), commercial and industrial construction, civil and infrastructure works, and thermal coal for power generation and industry | | Geography | 100% South Africa (Source: segment notes, all years) |

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1994
Nigel, South Africa
BRIDGETEC

BRIDGETEC Corp.

Premium
Information Technology

BRIDGETEC is a small Seoul-based enterprise software company that has built and maintained the telephony and customer-contact infrastructure of Korean banks, card issuers, insurers, public agencies and large enterprises for three decades. Its core platform, IPRON, is an IP contact-center and omnichannel routing suite. It sits alongside VELOCE (voice/screen recording and quality monitoring), IVR/visual ARS, speech recognition, voice biometrics and AI voicebot products, which together make up its AI Contact Center (AICC) and "Intelligence Contact Center" offerings. Most projects are won as a subcontractor or solution partner to the three national telecom carriers (KT, LG Uplus, SK Broadband/SK Telecom), which bid for and finance customer call-center builds. A smaller recurring business rents cloud contact-center capacity (IPRON Cloud, KT A'Cen Cloud partnership), and it holds public-cloud CSAP security certification. The company is debt-free and pays dividends consistently. It also holds a ~0.8% minority stake in K Bank, which listed on KOSPI in March 2026 and is material relative to BRIDGETEC's own market value. --- ### What the company does BRIDGETEC designs, develops, supplies, integrates and maintains software for corporate customer-contact centers. Morningstar's company profile, drawn from the company's regulatory description, characterises it as a software developer and supplier of: - AICC (AI contact center) systems - voicebots - speaker recognition - IPCC (IP contact center) - cloud contact center with CSAP security certification - visible (visual) ARS - IP-based wired/wireless multimedia services (intelligent network services, wireless mobile communication) It also runs a software rental business. Under this model it builds contact-center infrastructure from its own products and rents it to corporate customers, who pay for the period of use. The KIRS 2023 report divides the business into four lines: 1. **Call center business** (콜센터 사업). This line builds and maintains call-center infrastructure for financial institutions (banks, card companies, insurers, securities firms), service companies (hospitals, retail), public institutions, local governments and enterprises. It covers non-face-to-face customer channels over telephone, fax, e-mail and smart devices. 2. **Voice recognition business** (음성인식 사업). Described by KIRS as the newest line, it supplies speech-recognition IVR, dictation-based voice analytics (STT) and voice-biometric identity verification. 3. **Telecom business** (통신 사업). This line supplies media-server and application-server platforms, plus their application software, to Korean backbone carriers. The platforms run on the IP-based Broadband convergence Network (BcN) and support VoIP, 4G and 5G voice/video multimedia services, real-time information services (securities, weather, traffic) and directory assistance. 4. **Service business** (서비스 사업). The company builds large-capacity cloud call-center systems and rents them to companies that need a contact center. Customers pay according to the number of lines used, so there is no upfront construction cost. ### Business model and revenue model | Revenue type | Share of revenue | |---|---| | Product and integration (call center solutions) | ~72% | | Telecom platforms | ~9% | | Maintenance (service) | ~17% | | Cloud subscription (service) | ~2% | | Licensing as a standalone line | Not separately disclosed | The dominant model is project-based on-premise system construction followed by maintenance: **Construction (project) revenue:** KIRS 2023 explains the typical structure. When a bank or other client builds a contact center, a telecom carrier bids for the job. A contact-center infrastructure vendor such as BRIDGETEC then wins the carrier's subcontract. The carrier bears the construction cost and the client pays the carrier's telecom charges. Contracts usually run for 5–7 years. When a term ends, clients usually re-tender with new technology, because the carrier funds the build. This creates a recurring 5–7-year replacement cycle. BRIDGETEC's disclosed large contracts from 2021–2023 confirm the pattern: counterparties were LG Uplus, KT and SK Broadband, with end clients including Shinhan Bank, Woori Bank, Woori Card, Hana Card and the Korea Workers' Compensation & Welfare Service. **Maintenance revenue:** Ongoing support for installed systems. It was ₩9.8bn, about 17% of revenue, in FY2022 (KIRS 2023). **Cloud/rental (subscription-like) revenue:** Pay-per-use cloud contact-center services (IPRON Cloud, launched 2021). Partnership offerings include KT's A'Cen Cloud CCaaS (launched December 2022) and, historically, the KT "Call Center Service" (formerly Contact Plus) ASP model that BRIDGETEC began with KT in 2003. Cloud call-center revenue was small: ₩1.4bn in FY2022. **Telecom platform sales:** Lumpy, carrier-driven sales of media/application server platforms. **Revenue-model mix, FY2022** (KIRS 2023, the latest product-level split available in reviewed sources): ### Value-chain position BRIDGETEC is a Tier-2 solution vendor and integrator. It owns its core software IP (IPRON, VELOCE and the media platforms) and sells mostly through or alongside Korea's three carriers. The carriers act both as channel and as competitor: KT, LG Uplus and SK Telecom each run their own AICC businesses. Upstream, BRIDGETEC has historically licensed or partnered for speech technology, notably through a Nuance partnership from 2010. ### Customers and end-markets **Financial services:** Banks, card issuers, insurers and securities firms. This is the historical anchor. In 2017 the Korean press (Dealsite) described BRIDGETEC as the market-share leader in financial-sector call centers. A 2000s Digital Times article reported that it had supplied call-center construction and maintenance to 12 Korean banks, starting with Kwangju Bank. **Public sector:** Central ministries, local governments and public agencies, often via KT-led ASP/cloud models. CSAP certification (2023) qualifies BRIDGETEC to sell cloud services to public bodies. **Enterprises and services:** Hospitals, retail, manufacturing and service firms. **Telecom carriers:** Direct customers for BcN media/application platforms. ### Independent characterisation BRIDGETEC is a mature, domestic, project-driven contact-center infrastructure vendor of sub-scale size (₩49.7bn revenue in FY2025). Its strengths are a long installed base in Korean financial institutions, its own software stack, and a clean balance sheet. Its structural challenge is the migration of contact-center spending from on-premise builds, where it is strong, toward carrier- and hyperscaler-delivered cloud AICC and generative-AI services. Those services are dominated by much larger players (KT, LG Uplus, SK Telecom/Genesys, NAVER Cloud, Kakao). BRIDGETEC's revenue base has not grown over FY2021–FY2025, and margins have been thin and volatile.

Revenue$0.0B
Employees171
Market Cap$0.0B
Founded1995
United States, North America
bpost/

bpost SA/NV

Premium
Information Technology

Bnode is the corporate identity of bpost, Belgium's state-controlled universal postal operator, which over the past decade has been repositioning itself from a letter-mail incumbent into a parcel-centric logistics group. It now reports through three business units: Bpost (Belgian and Dutch last-mile mail, parcels, retail network and public services), Paxon (third-party e-commerce and omnichannel logistics, combining Radial in North America, Staci in France and internationally, and Active Ants in the Benelux), and Landmark Global (cross-border parcel management across Europe, North America and Asia). FY2025 operating income was EUR 4,482.3m with adjusted EBIT of EUR 179.7m, but the group recorded a second consecutive IFRS net loss and suspended dividends. 2026 has been marked by a five-week national strike and a guidance cut to roughly EUR 140m adjusted EBIT. The investment case rests on executing the #Reshape2029 transformation while mail revenues structurally erode. --- ### Company's own description In its 2026 interim report, Bnode describes itself as a group that provides national and international mail and parcel services — collection, transport, sorting and distribution of addressed and unaddressed mail, printed matter, newspapers and parcels — and that also sells postal, parcel, banking and financial products, e-commerce logistics, fulfilment, express delivery, proximity and convenience services and document management. It also performs Services of General Economic Interest (SGEI) on behalf of the Belgian State. In its press boilerplate, Bnode characterises itself as a digital expert in parcel logistics active across Europe, North America and Asia-Pacific, with more than 37,000 employees and 2025 turnover of EUR 4.48bn. At the June 2025 Capital Markets Day, management framed the ambition as becoming "a regional and digital expert in parcel-sized logistics" by 2029, explicitly repositioning from "a postal operator with logistics capabilities" to "a logistics leader that also provides postal services". ### Business model and revenue model The revenue model is almost entirely service-based and volume/price-driven; there is no material product, subscription or licensing revenue. Revenue streams fall into five economic categories: 1. **Regulated and quasi-regulated postal services (Bpost):** transactional mail, advertising mail, press distribution. Revenue = volume × price/mix. Volumes are in structural decline (domestic mail −10.0% in FY2025, −15.5% in H1 2026), offset partially by annual tariff increases (+6.1% price/mix in H1 2026). 2. **Domestic parcel delivery (Bpost):** B2C parcels in Belgium (EUR 542.1m in FY2025), contracted with marketplaces, e-tailers and SMEs. 3. **Public-service compensation and State contracts:** SGEI remuneration under the management contract with the Belgian State (EUR 77.7m in H1 2026), plus State service contracts (traffic-fine processing, licence plates, "679" accounts until 2025). 4. **Contract logistics / fulfilment (Paxon):** warehousing, pick-pack, returns, omnichannel distribution and commerce technology (payments, fraud), typically on multi-year contracts with transactional pricing per order/unit. 5. **Cross-border parcel management (Landmark Global):** customs brokerage, line-haul and last-mile orchestration on a per-shipment basis, increasingly driven by Asian e-commerce platforms. ### Value-chain position Bnode spans the middle and end of the e-commerce physical value chain: fulfilment (Paxon), cross-border middle-mile and customs (Landmark Global) and last-mile delivery (Bpost, plus partner carriers). Its distinctive Belgian asset is the densest physical retail and pickup network in the country (650+ post offices, 650+ post points, 2,800+ parcel lockers per H1 2026 report). ### Customer types and end-markets - Consumers and households (stamps, retail counters, parcel sending). - Businesses and public administrations (transactional and advertising mail). - Publishers (newspaper and periodical distribution under commercial contracts since the end of the press concession on 30 June 2024). - E-commerce marketplaces and retailers (domestic parcels; Chinese platforms are a significant driver of inbound Asian cross-border volume). - Brands and retailers requiring fulfilment and omnichannel logistics (Paxon; sectors include beauty and healthcare, telecom, retail, food and beverage and public sector per Staci description). - The Belgian State (SGEI, State services). No single external customer exceeds 10% of operating income, other than the Belgian federal government compensation (H1 2026 report, note 4). ### Independent characterisation Bnode is best understood as a melting ice cube financing a logistics pivot. The Belgian mail franchise still generated EUR 1,112.0m of domestic mail revenue in FY2025, but Bpost's adjusted EBIT margin compressed from 5.7% (FY2024) to 3.0% (FY2025) and to 1.5% in H1 2026. The strategic bet is that Paxon (EUR 1,691.5m FY2025 revenue) and Landmark Global (EUR 626.7m) can grow fast enough — and at sufficiently higher margins — to more than offset mail erosion. Execution has been uneven: Staci added scale but Radial North America has lost major clients (EUR 299.4m impairment in 2024, EUR 55.5m one-off restructuring charge in 2025). The group's low market capitalisation (c. EUR 0.3bn) against EUR 1.7bn net debt (including leases) leaves equity holders highly levered to transformation outcomes.

RevenueN/A
Employees33,808
Market CapN/A
FoundedN/A
Brussels, Belgium
BORATR

BORATR CO., Ltd.

Premium
Information Technology

BORATR is a specialist importer and distributor of premium Western, mainly Italian, food ingredients in South Korea. It is best known as the long-standing exclusive Korean partner of De Cecco (pasta, sauces, tomatoes, olive oil). Its portfolio also includes Spanish olive oil (Ybarra), dairy (Lactalis brands, Italian burrata and mozzarella), tomato products (Longobardi), foodservice sauces (Menu), vinegars and specialty items. Around 90% of its revenue comes from B2B channels: hotels, Italian restaurants, café and franchise chains, food manufacturers and large foodservice distributors. A growing consumer channel runs through online marketplaces and warehouse clubs. The company has around 47 staff and earns high gross margins (34–39%) for a distributor, because it holds exclusive import rights rather than competing on scale. It crossed KRW 100bn in revenue in FY2025. It is now trying to integrate backward into food manufacturing through a planned plant in Eumseong, North Chungcheong. Its controlling shareholder also chairs MGC Global, the operator of Mega MGC Coffee, Korea's largest coffee franchise by store count. --- ### What the company does BORATR imports branded, processed Western foodstuffs and sells them in Korea. It does not manufacture at scale today. Its revenue is almost entirely the resale of purchased goods ("상품매출"). Its IPO lead manager reported that goods sales made up 99.9% of FY2018 revenue, with the remaining 0.1% coming from cooking-class tuition fees (Daishin Securities, 27 Jun 2019). Disclosures over time show the business scaling up: **At IPO (2017):** about 500 SKUs from roughly 60 overseas suppliers in Italy, Spain, France, Greece, the US, Mexico and Thailand, sold to about 1,000 domestic customers (Hankyung; iNews24, May–Jun 2017). **In 2019:** about 300 SKUs from 40 suppliers, sold to about 1,400 customers, including large Korean foodservice distributors (Daishin, Jun 2019). The drop in SKUs and suppliers reflects portfolio rationalisation, which management at the time linked to supplier diversification problems. ### Business and revenue model | Dimension | Characterisation | |---|---| | Product vs. service | ~100% product resale (imported branded goods). Service revenue (cooking classes) is immaterial. | | Subscription / licensing | None | | Core economic moat | Exclusive Korean import rights. At IPO the company said it held exclusive contracts with about 60 overseas brands, including De Cecco, Longobardi, Lactalis, Menu, Ybarra and others. Exclusivity supports pricing because a single local importer can defend the brand's price position. | | Value chain position | Importer of record → bonded/warehouse logistics → B2B wholesale and foodservice distribution, plus direct-to-consumer e-commerce. It sits between European manufacturers and Korean foodservice operators, distributors and retailers. | | Planned extension | Manufacturing. A ~KRW 50bn food plant is planned on a 45,958 m² site at Yongsan Industrial Complex, Eumseong-gun, North Chungcheong (announced 3 Dec 2024). Earlier steps were an HMR (home meal replacement) line launched in Feb 2019 and an own consumer brand/storefront, "SEE21". | | Working-capital intensity | High. Inventory was KRW 39.1bn at FY2025 (38% of revenue), reflecting long ocean-freight supply chains from Europe and wide SKU breadth. | | Key cost drivers | Purchase prices in EUR and other foreign currencies, KRW exchange rates, ocean freight, domestic logistics (freight expense KRW 6.2bn in FY2025), and advertising (KRW 5.3bn in FY2025). | ### Customer types and end-markets **Foodservice (core):** Italian and Western restaurants, hotels, cafés and franchise chains, institutional caterers. **Industrial / B2B:** Food manufacturers and large food distributors buying ingredients. **Wholesale / retail:** Hypermarkets, warehouse clubs (De Cecco gift sets sold at Costco Korea list BORATR as importer and subsidiary C21 as customer contact), supermarkets. **Online consumer:** Marketplace storefronts (e.g., the "SEE21" minishop on Gmarket selling De Cecco sauces, Europomella burrata, Ybarra and Bonolio olive oils, Italian Parmesan). ### Company self-description vs. independent characterisation **Company's own description:** In DART filings the company classifies itself under "food, beverage and tobacco wholesale," with principal products listed as dairy products, sauces and pasta (IRGO listing based on company filings). Management has repeatedly described its ambition as becoming a "comprehensive food company": at IPO in 2017, under CEO Park Sung-chil in 2019, and again with the Eumseong plant in 2024. **Independent characterisation:** BORATR is a niche, brand-exclusive import distributor whose economics depend on three things: (i) keeping a handful of anchor supplier contracts, De Cecco above all; (ii) demand from Korea's Western-style dining sector; and (iii) KRW/EUR exchange rates. FY2025 showed the operating model scaling (revenue +11.9%). It also showed that the balance sheet has changed. Gross borrowings rose more than tenfold in two years and foreign-exchange losses absorbed almost all operating profit. A low-risk, cash-rich distributor has become a leveraged, FX-exposed company in the middle of a capex programme.

Revenue$0.1B
Employees47
Market CapN/A
Founded1993
United States, North America
BOOKOOK

BOOKOOK Securities Co., Ltd.

Premium
Information Technology

Bookook Securities is one of Korea's oldest independent, owner-controlled small brokerages, founded in 1954 and listed since 1988. It has no meaningful retail franchise. Its income comes overwhelmingly from proprietary fixed-income and derivatives trading, bond brokerage and arbitrage, and a niche corporate-finance and project-finance (IB) desk. It also owns a captive asset manager (Yurie Asset Management) and a new-technology finance arm (Bookook Capital, established 2023). The firm runs a conservative balance sheet, has a small headcount of about 290, and pays individual producers exceptionally well. It is best known in the market for a governance anomaly: 42.73% of its common shares are held in treasury, among the highest ratios of any Korean listed company. The 2026 Commercial Act amendment, which makes treasury-share cancellation mandatory, has turned this balance-sheet feature into the dominant equity narrative. That narrative drove a 105% share-price gain in 2025, a peak of KRW 103,300 in February 2026, and a 56% drawdown since. --- ### What the company does Bookook Securities is a licensed financial investment business under Korea's Financial Investment Services and Capital Markets Act. Its licences cover: - Dealing (proprietary trading); - Brokerage; - Underwriting and arranging (a securities licence for underwriting and placement was added in 1982); - Commodity futures dealing and brokerage (authorised 18 November 2009). Third-party business descriptions (Morningstar) list the following lines: retail brokerage, institutional brokerage, financial-product sales, corporate finance, project financing, structured financing, underwriting and M&A advisory. ### Company self-description No English-language annual report was retrievable. In a 2022 recruiting notice, the company describes itself in three ways: - It was the fourth securities firm established in Korea. - It was the first Korean brokerage to introduce independent profit-and-loss accounting at branch level. - It maintains "the soundest financial structure in the industry" through efficient management of its financial assets. The same notice calls the firm a "strong player in domestic IB" and announces a newly created Global Syndication team within its IB group. ### Independent characterisation The disclosed revenue mix shows that Bookook is, in economic substance, a principal-trading house with an IB overlay rather than a broker: - For 2Q26 operating revenue, Butler.works (from DART segment data) reports proprietary dealing at 84%, "other" at 8%, asset management (Yurie) at 6%, and brokerage at 1%. - Industry commentary in early 2025 credits the firm's results to bond and derivatives arbitrage in its trading division, which offset weaker IB income in 2024. - NICE Investors Service and press reports describe corporate finance (IB) as the firm's primary franchise. In practice that means real-estate PF, bridge loans, structured finance and bond underwriting. The firm has no scale in retail equity brokerage. This explains why Bookook has under-participated in the 2025–26 Korean trading-volume boom that lifted large retail brokers to record profits. ### Revenue model | Revenue type | Nature | Approximate weight | |---|---|---| | Proprietary trading and investment gains (bonds, derivatives, equities, arbitrage) | Gross trading gains, valuation and interest on trading book | Dominant (84% of 2Q26 gross operating revenue) | | Asset-management fees | Yurie Asset Management fund fees | About 6% of 2Q26 operating revenue | | Brokerage commissions | Retail and institutional equity/futures commissions; bond brokerage | About 1% of 2Q26 gross operating revenue | | IB fees | PF arrangement, underwriting, structured finance, advisory | Within "other" (8%); not separately disclosed | | Interest income | Loans, PF, deposits | Not separately disclosed | | Product / subscription / licensing | Not applicable | — | ### Value-chain position, customers and end-markets **Value-chain position:** a principal-capital provider and intermediary in Korean fixed income, derivatives and real-estate finance. **Customers:** institutional bond investors and issuers; corporate and real-estate developers (PF, bridge loans); a small retail and high-net-worth base served through the head-office sales department and a handful of branches; and fund investors in Yurie products. **End-markets:** the Korean bond market (KTB, credit, financial debentures), Korean equity and derivatives markets, Korean real-estate finance, and Korean venture/new-technology finance (through Bookook Capital).

RevenueN/A
Employees288
Market CapN/A
Founded1954
United States, North America
Bonne

Bonne Co., Ltd.

Premium
Information Technology

Bonne is a small-cap Korean beauty and household-products company with two businesses. The first is an asset-light ("fabless") cosmetics ODM business that designs, formulates and packages products for overseas brands and retailers, mainly US and European indie brands such as Pixi, and has production done by outside contract manufacturers. The second is a portfolio of owned brands, led by the colour-cosmetics line Touch in SOL. Since 2021 it has also owned a majority stake in Atosafe, an eco-positioned detergent, fabric-softener and oral-care brand company, which contributed about 39% of revenue in Q2 2026. Bonne grew to a peak of KRW 72.9B in revenue (FY2023) on US indie-brand demand. It then entered a crisis: an SFC accounting sanction for inventory overstatement, a trading halt, falling ODM orders, consecutive losses and a near-breach of KOSDAQ market-cap listing thresholds. In July–October 2026, control passed to former Ourhome Chairwoman Koo Mi-hyun, who injected about KRW 22.2B of new capital. The investment case is now a turnaround and control-change story rather than a growth story. --- ### What the company does Bonne operates in three areas: 1. **Cosmetics ODM/OEM.** Bonne develops products for third-party brands. Its services cover concept, formulation, packaging and component sourcing, then delivery of finished goods labelled with the client's brand. It owns no manufacturing plants: production is outsourced to contract manufacturers while Bonne keeps R&D, product planning and design. This model has been described as "factory-less" or asset-light (Cosinkorea, 6 Aug 2026; IB Tomato, 7 Aug 2026). Bonne reports exporting to about 30 countries and having launched seven of its own brands (IB Tomato, Aug 2026). Management says ODM work is turnkey, running from product planning to mass production, and that some products first launched in 2009 are still being reordered (Herald Economy, Mar 2026). 2. **Own cosmetics brands.** The main brands are Touch in SOL (colour cosmetics, sold historically at Sephora US, Ulta, CVS, Japanese drugstores and Korean home shopping, and since March 2026 on Olive Young online) and Stage Q (co-developed with Sephora China). 3. **Household and oral care (Atosafe subsidiary).** Atosafe sells laundry detergent (Shussler), fabric softener (Milk Cotton) and toothpaste (Denti Buongiorno) through Korean online and TV-shopping channels such as Home&Shopping and Coupang. Its products are made by OEM manufacturers (Dealsite, Jun 2023). In February 2026 it signed its first mainland China distribution agreement. The company's registered business purposes, as summarised by aggregators from its filings, are broad. They include baby care, bath, cleansing, eye make-up and colour cosmetics, fragrance, hair dye and hair care, nail, shaving, skincare, deodorant and depilatory products; import/export of cosmetics and health foods; wholesale and retail; chemical manufacturing; advertising; real-estate leasing; and detergent, toothpaste and lamp manufacturing and distribution (StockHub company profile). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Mostly product sales. ODM sales are B2B; brand and Atosafe sales are B2B2C through retailers and platforms. No material subscription or licensing revenue has been identified, although ODM sampling for subscription boxes (Boxycharm) was a meaningful channel in 2019–2022. | | Segment mix (Q2 2026) | Cosmetics 59%, detergent 39%, other 2% (Butler, segment split per Q2 2026 filing) | | Historical ODM/brand split | FY2020: ODM 64%, brand 34%, other 2% (SK Securities, 1 Apr 2021) | | Value-chain position | Mid-stream. Bonne sits between raw-material and packaging suppliers and contract manufacturers upstream, and brand owners and retailers downstream. It captures design and formulation margin without fixed-asset intensity. | | Customer types | US/European indie and celebrity beauty brands; global health-and-beauty retailers (Watsons, Mannings, Guardian, Cosway, Sephora); subscription-box operators (historically); Korean online platforms and TV home shopping; a Chinese distributor (Atosafe) | | End-markets | Colour cosmetics, skincare, personal care, household detergents and oral care. Main geographies are the US, Europe and Korea, with China emerging for Atosafe. | ### Company's own characterisation vs. independent view **Company view (latest management statements):** Bonne describes itself as a "global cosmetics company" offering a total solution from product planning through packaging design to marketing strategy. It says it reads the market through ODM and shapes it through its own brands (CEO Kang Eun-sil, Herald Economy, Mar 2026). **Independent characterisation:** In practice, Bonne's economics in FY2021–FY2024 depended on a small number of US indie-brand ODM clients. Pixi alone was 35–51% of ODM sales in 2020 (Hyundai Motor Securities, Jun and Dec 2020). This concentration explains both the FY2023–1Q24 earnings spike and the FY2025 collapse. The owned-brand business has historically consumed marketing spend; management attributed recent losses partly to marketing costs from a renewed domestic brand push over the past two years (IB Tomato, Aug 2026). Atosafe gives revenue ballast but has little visible profitability. After the change of control, the press has openly debated whether Bonne will remain an operating ODM company or become an acquisition platform for the Koo family (Cosinkorea, Aug 2026).

RevenueN/A
Employees57
Market CapN/A
Founded2009
United States, North America
BNK

BNK Financial Group Inc.

Premium
Information Technology

| Field | Detail | |---|---| | Entity profiled | BNK Financial Group Inc. (Korean: BNK금융지주). This is the same listed entity as in the identification list; no change of listing or ticker. | | Legal name | BNK Financial Group Inc. | | Former name | BS Financial Group Inc.; renamed to BNK Financial Group in April 2015 [S21][S68] | | Founding of holding company | March 2011 (holding company formed above Busan Bank); the group traces its banking roots to Busan Bank, founded 1967 [S68] | | Incorporation jurisdiction | Republic of Korea | | Headquarters | Munhyeon Financial Complex, Nam-gu, Busan, South Korea (co-located with BNK Busan Bank head office) [S80]. Street address commonly cited as 30 Munhyeongeumyung-ro, Nam-gu, Busan (not re-verified in this review). | | Exchange / ticker | Korea Exchange, KOSPI, 138930 (Yahoo-style: 138930.KS) | | ISIN | KR7138930003 (standard KRX format for code 138930; not re-verified against KRX in this review) | | CUSIP | Not applicable (no US listing) | | Fiscal year end | 31 December [S20] | | Par value per share | KRW 5,000 [S19] | | Paid-in capital | KRW 1,629.7 bn [S19] | | Shares outstanding | 310,327,033 as of July 2026 [S17][S19]. About 3.49 m treasury shares bought back in H1 2026 were scheduled for cancellation in Q3 2026 [S4][S6]; implied post-cancellation count approx. 306.8 m (derived, cancellation completion not independently confirmed). | | Employees | Not publicly disclosed in the sources reviewed (group headcount) | | External auditor | — | | Market capitalisation | KRW 5,598.3 bn at KRW 18,040 close on 24 July 2026 [S19]; KRW 5,359 bn at KRW 17,270 close on 28 July 2026 [S18]. | | Website | www.bnkfg.com | | Chairman & CEO | Bin Dae-in (second term, through March 2029) [S22][S23] | | Group CFO | Park Seong-uk, EVP (CFO as of July 2026) [S4][S8] | BNK Financial Group is South Korea's largest regional financial holding company by total assets and net profit, anchored in the Busan–Ulsan–Gyeongnam ("Bu-Ul-Gyeong", south-east Korea) economic region. It owns two regional commercial banks — BNK Busan Bank and BNK Kyongnam Bank — which together generate the large majority of group earnings, alongside seven non-bank subsidiaries spanning specialised lending (BNK Capital), brokerage and investment banking (BNK Investment & Securities), savings banking, asset management, venture capital, credit information and IT services. Group consolidated assets reached KRW 167.48 trn at end-June 2026 [S1-H1: S5]. The franchise is deeply tied to the region's shipbuilding, maritime, manufacturing, defence and logistics industries, which supports loan growth and fee opportunities but concentrates credit risk in a slowing, ageing regional economy. The equity story since 2024 rests on a "value-up" programme targeting a 10%+ ROE and a 50%+ shareholder return ratio, set against persistent governance scrutiny from regulators and activist shareholders. --- ### What the company does BNK Financial Group is a pure holding company; its revenue arises from the operating subsidiaries it consolidates. Through those subsidiaries the group provides commercial banking (deposits, corporate and SME loans, household and mortgage lending, trade finance, treasury), specialised credit (auto, equipment and consumer finance, leasing), securities brokerage and investment banking, collective investment management, savings-bank lending, venture capital, credit investigation and debt collection, and group IT system development [S68]. ### Company's own characterisation In its public communications, the group frames its role around three pillars: being the core financial partner for regional growth in Bu-Ul-Gyeong, expanding "productive finance" to strategic regional industries, and lifting shareholder value through its corporate value-up plan. Its January 2026 reorganisation explicitly cited support for regionally led growth, productive-finance-based sustainable finance, consumer protection with integrated internal controls, and shareholder value [S42]. ### Independent characterisation Analytically, BNK is a spread-driven regional bank group: **Revenue model:** Predominantly net interest income. In FY2025 group net interest income was KRW 2,953.1 bn versus non-interest income of KRW 416.8 bn [S1], i.e. interest income was roughly 88% of net operating revenue (derived). There is no meaningful product-sale, subscription or licensing revenue; fees (lending, card, wealth-product distribution, brokerage, asset management) form the secondary engine. **Value-chain position:** Balance-sheet lender and deposit-taker at the core of the regional credit system, with non-bank subsidiaries adding higher-yield lending (capital) and capital-markets fee income (securities, asset management). **Customer types:** Regional SMEs and mid-sized manufacturers (notably shipbuilding and marine supply chains), large-corporate borrowers (increasingly sourced in the Seoul metropolitan area), retail depositors and borrowers, local governments and public institutions, and real-estate project-finance (PF) sponsors. **End-markets:** Busan, Ulsan and South Gyeongsang Province primarily; the Seoul metropolitan area for selected corporate lending; and, via BNK Capital, small overseas consumer and microfinance markets in Southeast and Central Asia. **Earnings mix trend:** Non-bank subsidiaries are rising in importance. In H1 2026, non-bank net profit was KRW 172.6 bn (+58.6% YoY) while banking was KRW 356.2 bn (-13.2% YoY) [S4][S5].

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2011
Busan, South Korea
Blu

Blu Label Unlimited Group Limited

Premium
Information Technology

Blu Label Unlimited is South Africa's largest independent distributor of prepaid virtual value: airtime, data, prepaid electricity, universal vouchers, ticketing, SIM starter packs and handsets, routed through a national network of retail, banking, informal-trade and digital touchpoints. Because PINless airtime, prepaid electricity, ticketing and vouchers are booked on a commission (agency) basis, reported revenue of R13.1bn (FY2026) materially understates the R99.9bn of gross value transacted through the platform [AFS26]. For most of the past decade, the group's equity story was dominated by its 2017 investment in mobile operator Cell C. With Cell C restructured and separately listed on the JSE in November 2025, Blu Label now holds a 49.53% associate stake (including a 15.95% block held for sale) and is repositioning itself as an "essential-services platform" spanning distribution and payments, data intelligence, embedded finance (BluAdvance) and infrastructure and energy (Cigicell, BluEnergy) [AFS26; Engineering News, 26 Aug 2026]. --- ### Company's own description (latest filing) In its FY2026 Directors' Report, the company describes its core business as the virtual distribution of secure electronic tokens of value and transactional services across its footprint of touchpoints. Its stated strategy is to extend that footprint organically and through acquisitions, to meet demand for the delivery of multiple prepaid products through a single distributor across various delivery mechanisms and merchants [AFS26, Directors' Report]. The FY2026 strategic review adds that the group is increasingly positioned as an essential-services platform spanning distribution and payments, data intelligence, embedded financial services, and infrastructure and energy, with FY2027 priorities of cash generation, balance-sheet flexibility, execution and disciplined capital allocation [AFS26]. ### Independent characterisation Blu Label is best understood as a transaction-switching and float-intensive distribution utility sitting between South Africa's mobile network operators (MNOs), municipalities/Eskom and voucher issuers on one side, and banks, retailers, informal merchants and fintech apps on the other. Its economics are a thin margin on very large gross flows (commissions on PINless top-ups and electricity), supplemented by principal-basis sales of physical/virtual PIN inventory (where full face value is booked as revenue), SIM starter-pack annuities, handset distribution, and newer higher-margin adjacencies (airtime/electricity advances, data analytics, municipal revenue assurance). The defining structural change in FY2026 was the exit from consolidated telecom-operator exposure. Until November 2025, Blu Label carried Cell C's funding instruments, airtime inventory, loans and the Comm Equipment Company (CEC) postpaid-financing subsidiary on its balance sheet. These were unwound or transferred into the separately listed Cell C, leaving Blu Label with (i) an operating distribution/payments business and (ii) a listed equity stake in Cell C [AFS26]. ### Revenue model mix | Revenue source (per AFS26 note 1.2) | Accounting basis | Nature | |---|---|---| | Prepaid airtime & data — physical and virtual PIN | Principal; full face value recognised | Product sale | | Prepaid airtime & data — PINless | Agent; commission only | Transaction fee | | Commissions, bonuses, incentives from MNOs | Contractual, recognised monthly | Rebate/annuity | | Postpaid/hybrid airtime contracts | Principal; recognised over time | Subscription-like (largely exited with CEC transfer) | | SIM cards, activation bonuses, ongoing revenue share | Principal on SIM; variable consideration recognised when received | Annuity | | Services (location-based, SMS, VAS/media, call centre, data, technology, payment provision) | Principal or agent depending on contract | Service | | Electricity commissions | Agent; commission primarily on kWh | Transaction fee | | Ticketing and universal vouchers | Agent; gross profit only recognised | Transaction fee | | Finance revenue (e.g. handset financing, advances) | Interest | Lending | Product vs. service vs. subscription split by rand value is n/d; the group does not publish revenue disaggregated by these categories in the material reviewed. ### Value-chain position, customers and end-markets **Upstream suppliers:** Vodacom, MTN, Cell C, Telkom (airtime/data/SIMs); Eskom and municipalities (prepaid electricity); voucher, ticketing and content providers. **Customers/channels:** One external customer accounted for R2.3bn of Africa Distribution revenue in FY2026 [AFS26]. Channels include national retailers, banks (BluVoucher growth was driven by financial-institution channels), informal merchants, and app/aggregator integrations [AFS26]. **End-markets:** South African prepaid mobile, prepaid electricity, consumer digital payments, municipal revenue collection, and (prospectively) renewable-energy trading. Revenue from customers outside South Africa was only R3.8m in FY2026 [AFS26].

Revenue$0.7B
EmployeesN/A
Market CapN/A
Founded2001
Johannesburg, South Africa
BKTOPS

BK TOPS Co., Ltd.

Premium
Information Technology

BK TOPS is the shell-like remnant of Tongyang Networks, once the IT-services and MRO arm of the Tongyang Group. The group collapsed in September–October 2013, when Tongyang Networks and four sister companies entered court rehabilitation. After rehabilitation, changes of control, and a 2019–2020 spin-off of its legacy IT outsourcing and SI business into an unlisted 100% subsidiary, the listed entity tried a series of unrelated new ventures: industrial-scrap recycling (the former Woongjin Sangju Polysilicon plant assets), mask manufacturing via U-Line Korea, home-appliance distribution, and B2B purchasing-agency/MRO distribution. Revenue shrank to low single-digit billions of won. Losses mounted and the company slid into capital impairment. Governance controversies followed, including alleged fabricated board minutes and disputed handling of contract deposits. Two consecutive audit disclaimers ended its listing in May 2024. For analytical purposes it is a case study in post-chaebol-collapse value destruction rather than a going-concern investment. --- **The company's own description (latest available).** As of end-2022, BK TOPS described its main business as distribution services for maintenance, repair and operating (MRO) supplies, delivered through product distribution and B2B purchasing-agency transactions (The Fact, Aug 2023, citing the company's filings). By early 2024 the press summarised its activities as household-appliance distribution, intermediate recycling processing, and mask sales (Asia Economy, Mar 2024). Aggregator roic.ai describes it as a diversified technology and distribution company. In recent periods, revenue historically came from IT services, distribution, mask production and recycling. **Independent characterisation.** By 2021–2023 BK TOPS was in practice a holding vehicle for a set of small, low-margin, asset-light trading activities. None reached scale. The original economic engine, IT outsourcing and system integration for Tongyang affiliates and Standard Chartered Bank Korea, eroded after the 2013 group collapse. Standard Chartered cancelled its contracts during rehabilitation, leaving mainly legacy Tongyang Life and Yuanta Securities work (etoday, Oct 2015, citing SGA). That engine was ring-fenced into an unlisted subsidiary effective 3 March 2020. The listed company then pursued opportunistic, capital-markets-funded "new businesses" financed with convertible bonds. The most notable was a roughly KRW 31 billion purchase of plant machinery and ferrous/non-ferrous scrap from the idle Sangju polysilicon plant, intended for resale as used equipment and scrap (Asia Economy, Feb 2021). **Business model and revenue mix (as far as disclosed):** **Value-chain position:** an intermediary/trader in commodity-like goods (scrap, consumables, appliances) with no proprietary technology after the IT spin-off. **Customer types:** enterprise and B2B buyers; retail channels for masks and appliances (specific named customers not disclosed after 2015). **End-markets:** Korean industrial MRO, steel-scrap recycling, personal protective equipment, consumer electronics distribution.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1991
Seoul, South Korea
Biosolution

Biosolution Co., Ltd.

Premium
Information Technology

Biosolution is a Seoul-based advanced regenerative medicine company. It is one of the few Korean cell-therapy developers with several marketed, reimbursed products and recurring revenue. Its franchise is cartilage regeneration. CartiLife is an autologous, scaffold-free, costal-cartilage-derived chondrocyte bead therapy for knee cartilage defects. It moved from conditional (2019) to full Korean approval (April 2025), holds FDA RMAT designation, has completed a US Phase 2, and in April 2026 became the first Korean cell therapy approved for sale in China's Hainan Boao Lecheng medical pilot zone. Two follow-on assets extend the platform: the allogeneic pellet Cartiroid (Australian Phase 1/2) and the injectable spheroid Spherocure (Korean Phase 1/2a). Burn-care therapies (KeraHeal, KeraHeal-Allo), OECD-listed human tissue models, and stem-cell cosmetic ingredients add diversified but sub-scale revenue. The company remains loss-making at the operating level (FY2025 operating loss KRW 4.3bn on revenue of KRW 15.2bn). It also controls the restructured gene-therapy developer Helixmith. --- ### What the company does Biosolution develops, manufactures and sells cell-based products built on two core competencies: somatic and stem-cell culture, and tissue engineering. Commercial activity falls into four streams [company website; Bloter/Daum, Apr 2026; Butler, Q1 2026]: 1. **Cell therapeutics.** Autologous and allogeneic products for cartilage defects and burns: - CartiLife (knee cartilage) - KeraHeal (autologous spray-type keratinocytes for severe burns) - KeraHeal-Allo (allogeneic keratinocytes in thermosensitive hydrogel for deep second-degree burns) This is the largest stream: 65.3% of FY2025 revenue and about 71% of Q1 2026 revenue. 2. **Cosmetic materials and finished cosmetics.** Human stem-cell conditioned media (STEMSOO / STem水), peptide and exosome ingredients, natural ingredients, and a direct-to-consumer brand mall (stemsoo.com). 18.7% of FY2025 revenue. 3. **Human tissue models and non-clinical testing services.** KeraSkin skin model, MCTT HCE epithelial model, plus cartilage and intestinal models. Sold as kits and as GLP-certified alternative-to-animal testing (CRO) services. 10.1% of FY2025 revenue. 4. **Medical devices / merchandise and other services.** For example, the StemMobile-Gel wound dressing. About 6% of FY2025 revenue combined. ### Business and revenue model | Revenue type (FY2025) | KRW bn | Share of revenue (%) | |---|---|---| | Products: cell therapies | 9.9 | 65.3 | | Products: cosmetic materials and finished goods | 2.8 | 18.7 | | Products and services: human tissue models | 1.5 | 10.1 | | Merchandise (incl. medical devices) | 0.4 | about 2.6 (derived) | | Other services | 0.5 | about 3.3 (derived) | **Product sales (dominant):** Cell therapies are manufactured per patient or per batch in the company's Seoul GMP facility and sold to hospitals. CartiLife has been sold through a direct sales team since 2023 [KIRS, Jul 2024; Research Arum, Mar 2023]. KeraHeal-Allo was historically distributed exclusively in Korea by Mundipharma Korea under a May 2016 agreement [Medigate News, May 2016]. Whether that agreement is still in force is not publicly disclosed. **Licensing / technology fees (emerging):** In China (Hainan), a local partner handles sales. Biosolution receives a share of the treatment price as a technology fee [ValueFinder via Asia Economy, Jun 2026]. Management describes procedure-volume growth there as flowing to revenue without large local capital investment [Money Today, Aug 2026]. Out-licensing of CartiLife (US Phase 3 and other ex-Korea rights), Cartiroid and Spherocure is an explicit goal [Asia Economy, Jun 2026]. **Services:** GLP non-clinical testing using in-house tissue models, plus cosmetic ingredient development and consulting [company website]. **Subscription:** none disclosed. **Product vs. service mix, FY2025:** [Bloter/Daum, Apr 2026, citing company IR]: ### Value chain position Biosolution is vertically integrated from cell-sourcing protocol and process development through GMP manufacture and quality release, and into hospital sales in Korea. For CartiLife the chain runs: 1. Biopsy of the patient's costal (rib) cartilage. 2. Cell isolation and culture in Biosolution's Seoul GMP plant. 3. Formation of scaffold-free cartilage beads. 4. Implantation by an orthopaedic surgeon. In China the company has chosen an asset-light model: production at the partner Boao International Hospital's own GMP facility, local sales by the partner, and a technology fee to Biosolution [Dailypharm, Aug 2026]. In tissue models it is both a kit manufacturer and a testing-service provider. ### Customers and end markets | End market | Customer type | Products | |---|---|---| | Orthopaedics: cartilage defects / early knee OA | Tertiary and general hospitals, specialty joint hospitals (Korea); Boao International Hospital (China) | CartiLife; pipeline Cartiroid, Spherocure | | Burns and wound care | Burn-specialist hospitals; reimbursed under national health insurance and industrial-accident insurance | KeraHeal, KeraHeal-Allo; StemMobile-Gel | | Chemical, cosmetic, drug and device safety testing | Cosmetics, pharma, chemical and device makers; regulators | KeraSkin, MCTT HCE and other models; GLP testing | | Cosmetics | Cosmetic brand owners (B2B ingredients), consumers (B2C) | STEMSOO, BSP-11, exosome ingredients | ### Company self-description vs. independent characterisation | Tier | Product | Status | |---|---|---| | Premium autologous | CartiLife | Marketed in Korea and Hainan | | Mass-producible allogeneic | Cartiroid | Clinical | | Non-surgical injectable DMOAD candidate | Spherocure | Clinical | **Company's own description.** The website presents Biosolution as "A Leading Company of Cell-Based Biotechnology". Filings-based database summaries describe it as a cell-based biotechnology company that manufactures and sells cell-therapy products, develops cell-therapeutics technology, and produces human tissue models for toxicity and efficacy screening [Morningstar profile]. **Independent characterisation.** Biosolution is best viewed as a small, commercial-stage regenerative-medicine company whose valuation depends on one platform: costal chondrocyte tissue engineering. That platform has three tiers: Around this core sit modest, steady businesses (burns, tissue models, cosmetics). These provide about KRW 5–6bn of non-cartilage revenue but do not cover R&D. The Helixmith stake adds a large, volatile equity-accounted asset and an option on Helixmith's assets: Engensis royalties from China, GMP and animal facilities, and cash. It is not an operating business that Biosolution consolidates.

Revenue$0.0B
Employees100
Market CapN/A
Founded2000
United States, North America
Biogena

Biogena Group Invest Ag

Premium
Information Technology

**Data conflict on market capitalisation.** The Wiener Börse instrument page carries a reference price of 41.55, a market cap of EUR 5.9m and a YTD of −26.96% [S3]. These are inconsistent with all 2026 press coverage, which reports prices of roughly EUR 3–5.40, YTD gains of 76–83%, and a market cap of EUR 17.72m in June 2026 [S11][S13]. The exchange page appears to be a stale or cached snapshot and is disregarded here. Biogena Group Invest AG is a thinly capitalised listed holding vehicle whose value derives almost entirely from its minority interest in the BIOGENA operating structure. Press reporting puts that interest at roughly 4% of the Austrian sales company [S4]. BIOGENA itself, founded in Salzburg in 2006 by Dr. Albert Schmidbauer, is Austria's market leader in science-based premium micronutrient preparations made on the "pure substance" principle, meaning no colourants or preservatives. It produces in Austria and sells in more than 70 countries [S30][S7]. The group reported revenue of about EUR 124.9m and EBITDA of about EUR 19.1m in FY2024/25 [S12]. It is pursuing a "Vision 2030" target of roughly EUR 500m in revenue through direct-to-consumer channels, German expansion, flagship "PLAZA" health destinations, and a first entry into pharmacies [S8][S10][S12][S23]. For investors, Group Invest is now a merger-arbitrage instrument: each share converts into 0.879197 Biogena Good Vibes shares upon registration [S30]. --- **What the listed entity does.** - Biogena Group Invest AG is a holding company with no operations of its own. When it listed in 2020, the Vienna Stock Exchange described it as the issuer behind the central operating Biogena Group Invest GmbH & Co KG [S2]. - When it moved up to direct market plus, the exchange described it as a shareholder in the Biogena Group [S1]. - Regional press (July 2026) reports that it holds roughly four percent of the Austrian sales subsidiary. International distribution runs through Biogena International, which sits entirely within the new top holding [S4]. - Its standalone income is therefore participation income. An aggregator shows revenue of about USD 402k, EBITDA of about USD 340k and net income of about USD 336k for the latest fiscal year (fiscal year unspecified; n/v) [S25]. **What the BIOGENA GROUP does: company's own description.** The group describes itself as follows: - An internationally oriented "361° Health" company exporting to more than 40 countries (older profile text) [S3]. More recent filings say more than 70 countries [S30]. - Its core business is developing, producing and selling science-based premium micronutrient preparations under the pure-substance principle. It also positions itself as a knowledge and service partner in health, nutrition and well-being [S3]. - Stated focus areas are iron, mineral and osteoporosis product innovations, and integrated solutions in occupational health promotion and diagnostics [S3][S30]. - In its September 2026 listing communication, it calls itself a health group focused on micronutrients, diagnostics, prevention, longevity and personal health guidance. It develops and produces in Austria and sells through digital channels, medical and therapeutic partners, pharmacies, and its own stores and PLAZAs [S21]. **Business model.** BIOGENA is a vertically integrated brand owner covering the full value chain: **Revenue model mix.** - The group does not publish a product vs. service vs. subscription split (n/d). - Analytically, revenue is predominantly product sales of supplements, sold both B2B2C through practitioners and D2C through stores and online. - Diagnostics, PLAZA treatments, Academy training and workplace health programmes add a smaller services layer. - BIOGENA ONE is positioned as a "daily health routine" [S12]. This suggests recurring purchase behaviour, but no subscription revenue is disclosed. **Customer types and end-markets.** - More than 1 million customers in over 70 countries [S20]. - Physicians and therapists using products alongside medical treatment or for prevention [S3]. - Health-conscious consumers, including sports, aesthetics and longevity segments. - Corporate clients (occupational health) [S30]. - Pet owners (BIOGENA PETS) [S33]. **Independent characterisation.** BIOGENA sits at the premium, practitioner-endorsed end of the European supplements market. It is distinctive in combining three things: owned manufacturing, a practitioner channel, and an experiential retail format (PLAZAs offering diagnostics, cold saunas and oxygen chambers [S6]). Its scale is small compared with multinational consumer-health players. Its growth record is unusually strong: - Average growth of roughly 27% a year since founding [S28]. - +44% in FY2024/25 [S6]. Its capital-markets profile is unconventional: - Retail "community financing" since 2015: more than EUR 17m raised over 16 rounds from about 2,100 private investors [S19]. - Retail growth bonds [S28][S8]. - A retail-heavy share offering in 2026 [S20].

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded2020
Salzburg, Austria

Page 211 of 482

1…210211212…482

Page 211 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo